40,TPP0010,O
40,.1177,NUMBER
40,/,O
40,2045125320935306Therapeutic,O
40,Advances,O
40,in,O
40,Psychophar,O
40,‐,O
40,macologyD,O
40,Bishara,PERSON
40,.,O
40,C,O
40,Kalafatis,O
40,Therapeutic,O
40,Advances,O
40,in,O
40,Psy,O
40,‐,O
40,chopharmacology,O
40,Emerging,O
40,and,O
40,experimental,O
40,treatments,O
40,for,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,and,O
40,drug,O
40,interactions,O
40,with,O
40,psychotropic,O
40,agents,O
40,Delia,PERSON
40,Bishara,PERSON
40,Ther,PERSON
40,Adv,O
40,Psychopharmacol,O
40,.,O
40,Chris,PERSON
40,Kalafatis,PERSON
40,and,O
40,David,PERSON
40,Taylor,PERSON
40,Abstract,O
40,:,O
40,As,O
40,yet,O
40,.,O
40,no,O
40,agents,O
40,have,O
40,been,O
40,approved,O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,although,O
40,several,O
40,experimental,O
40,drugs,CRIMINAL_CHARGE
40,are,O
40,being,O
40,used,O
40,off,O
40,licence,O
40,.,O
40,These,O
40,may,O
40,have,O
40,serious,O
40,adverse,O
40,agents,O
40,being,O
40,used,O
40,across,O
40,the,O
40,world,O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,and,O
40,investigated,O
40,their,O
40,drug,O
40,interaction,O
40,potential,O
40,with,O
40,psychotropic,O
40,agents,O
40,using,O
40,several,O
40,drug,O
40,interaction,O
40,databases,O
40,and,O
40,resources,O
40,.,O
40,A,O
40,preliminary,O
40,search,O
40,identified,O
40,the,O
40,following,O
40,drugs,CRIMINAL_CHARGE
40,as,O
40,being,O
40,used,O
40,to,O
40,treat,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,symptoms,O
40,:,O
40,atazanavir,O
40,(,O
40,ATV,O
40,),O
40,.,O
40,azithromycin,O
40,(,O
40,AZI,O
40,),O
40,.,O
40,chloroquine,O
40,(,O
40,CLQ,O
40,),O
40,/,O
40,hydroxychloroquine,O
40,(,O
40,HCLQ,O
40,),O
40,.,O
40,dipyridamole,O
40,.,O
40,famotidine,O
40,(,O
40,FAM,O
40,),O
40,.,O
40,favipiravir,O
40,.,O
40,lopinavir,O
40,/,O
40,ritonavir,O
40,(,O
40,LPV,O
40,/,O
40,r,O
40,),O
40,.,O
40,nitazoxanide,O
40,.,O
40,remde,O
40,‐,O
40,sivir,O
40,.,O
40,ribavirin,O
40,and,O
40,tocilizumab,O
40,.,O
40,Many,O
40,serious,O
40,adverse,O
40,effects,O
40,and,O
40,potential,O
40,drug,O
40,interactions,O
40,with,O
40,psychotropic,O
40,agents,O
40,were,O
40,identified,O
40,.,O
40,The,O
40,most,O
40,problematic,O
40,agents,O
40,were,O
40,found,O
40,to,O
40,be,O
40,ATV,O
40,.,O
40,AZI,O
40,.,O
40,CLQ,O
40,.,O
40,HCLQ,O
40,.,O
40,FAM,O
40,and,O
40,LPV,O
40,/,O
40,r,O
40,in,O
40,terms,O
40,of,O
40,both,O
40,pharmacokinetic,O
40,as,O
40,well,O
40,as,O
40,serious,O
40,pharmacodynamic,O
40,drug,O
40,interactions,O
40,.,O
40,including,O
40,QTc,O
40,prolongation,O
40,and,O
40,neutropenia,O
40,.,O
40,Significant,O
40,caution,O
40,should,O
40,be,O
40,ex,O
40,‐,O
40,ercised,O
40,if,O
40,using,O
40,any,O
40,of,O
40,the,O
40,medications,O
40,being,O
40,trialled,O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,until,O
40,robust,O
40,clinical,O
40,trial,O
40,data,O
40,are,O
40,avail,O
40,‐,O
40,able,O
40,.,O
40,An,O
40,even,O
40,higher,O
40,threshold,O
40,of,O
40,vigilance,O
40,should,O
40,be,O
40,maintained,O
40,for,O
40,patients,O
40,with,O
40,pre,O
40,‐,O
40,existing,O
40,conditions,O
40,and,O
40,older,O
40,adults,O
40,due,O
40,to,O
40,added,O
40,toxicity,O
40,and,O
40,drug,O
40,interactions,O
40,.,O
40,especially,O
40,with,O
40,psychotrop,O
40,‐,O
40,ic,O
40,agents,O
40,.,O
40,Keywords,O
40,:,O
40,adverse,O
40,effects,O
40,.,O
40,drug,O
40,‐,O
40,interactions,O
40,.,O
40,psy,O
40,‐,O
40,chotropic,O
40,drugs,CRIMINAL_CHARGE
40,.,O
40,treatment,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,Although,O
40,no,O
40,treatments,O
40,have,O
40,been,O
40,approved,O
40,or,O
40,shown,O
40,to,O
40,be,O
40,safe,O
40,and,O
40,effective,O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,there,O
40,are,O
40,several,O
40,treatments,O
40,being,O
40,used,O
40,off,O
40,licence,O
40,either,O
40,on,O
40,a,O
40,compassionate,O
40,‐,O
40,use,O
40,basis,O
40,or,O
40,as,O
40,part,O
40,of,O
40,a,O
40,randomised,O
40,controlled,O
40,trial,O
40,.,O
40,The,O
40,South,LOCATION
40,London,CITY
40,and,O
40,Maudsley,ORGANIZATION
40,NHS,ORGANIZATION
40,Foundation,ORGANIZATION
40,Trust,O
40,does,O
40,not,O
40,currently,DATE
40,recommend,O
40,initiating,O
40,these,O
40,drugs,CRIMINAL_CHARGE
40,.,O
40,Howev,O
40,‐,O
40,er,O
40,.,O
40,clinicians,O
40,need,O
40,to,O
40,be,O
40,aware,O
40,of,O
40,their,O
40,adverse,O
40,effects,O
40,and,O
40,po,O
40,‐,O
40,tential,O
40,drug,O
40,interactions,O
40,with,O
40,psychotropic,O
40,agents,O
40,in,O
40,case,O
40,they,O
40,are,O
40,prescribed,O
40,elsewhere,O
40,to,O
40,patients,O
40,from,O
40,our,O
40,services,O
40,.,O
40,Serious,O
40,adverse,O
40,effects,O
40,are,O
40,associated,O
40,with,O
40,these,O
40,drugs,CRIMINAL_CHARGE
40,.,O
40,and,O
40,these,O
40,may,O
40,overlap,O
40,with,O
40,the,O
40,clinical,O
40,manifestations,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,Chloroquine,O
40,(,O
40,CLQ,O
40,),O
40,/,O
40,hydroxychloroquine,O
40,(,O
40,HCLQ,O
40,),O
40,.,O
40,azithromycin,O
40,(,O
40,AZI,O
40,),O
40,.,O
40,and,O
40,lopinavir,O
40,/,O
40,ritonavir,O
40,(,O
40,LPV,O
40,/,O
40,r,O
40,),O
40,are,O
40,associated,O
40,with,O
40,a,O
40,range,O
40,of,O
40,ad,O
40,‐,O
40,verse,O
40,effects,O
40,.,O
40,including,O
40,QTc,O
40,prolongation,O
40,.,O
40,torsade,O
40,de,O
40,pointes,O
40,.,O
40,hepatitis,O
40,.,O
40,acute,O
40,pancreatitis,CAUSE_OF_DEATH
40,and,O
40,neutropenia,O
40,.1,NUMBER
40,Considering,O
40,that,O
40,most,O
40,patients,O
40,who,O
40,have,O
40,died,O
40,from,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,were,O
40,elderly,O
40,and,O
40,had,O
40,underlying,O
40,health,O
40,conditions,O
40,including,O
40,cardiovascular,O
40,comorbidi,O
40,‐,O
40,ties,O
40,.,O
40,CLQ,O
40,/,O
40,HCLQ,O
40,.,O
40,AZI,O
40,.,O
40,and,O
40,LPV,O
40,/,O
40,r,O
40,could,O
40,potentially,O
40,increase,O
40,the,O
40,risk,O
40,of,O
40,cardiac,O
40,death,O
40,.,O
40,In,O
40,addition,O
40,.,O
40,hepatitis,O
40,and,O
40,leucopoenia,O
40,are,O
40,clinical,O
40,manifestations,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,and,O
40,so,O
40,the,O
40,use,O
40,of,O
40,these,O
40,drugs,CRIMINAL_CHARGE
40,could,O
40,worsen,O
40,both,O
40,hepatic,O
40,and,O
40,bone,O
40,marrow,O
40,dysfunction,O
40,.,O
40,It,O
40,would,O
40,also,O
40,be,O
40,almost,O
40,impossible,O
40,to,O
40,differentiate,O
40,the,O
40,drug,O
40,‐,O
40,related,O
40,adverse,O
40,effects,O
40,from,O
40,the,O
40,disease,CAUSE_OF_DEATH
40,manifestations,O
40,.1,NUMBER
40,Correspondence,O
40,to,O
40,:,O
40,Delia,PERSON
40,Bishara,PERSON
40,Maudsley,PERSON
40,Hospital,PERSON
40,.,O
40,Denmark,COUNTRY
40,Hill,LOCATION
40,.,O
40,Camberwell,O
40,.,O
40,London,CITY
40,SE5,O
40,Chris,PERSON
40,Kalafatis,PERSON
40,David,PERSON
40,Taylor,PERSON
40,South,LOCATION
40,London,CITY
40,and,O
40,Maudsley,PERSON
40,NHS,ORGANIZATION
40,Foundation,ORGANIZATION
40,Trust,ORGANIZATION
40,.,O
40,London,CITY
40,.,O
40,UK,COUNTRY
40,Several,O
40,clinical,O
40,trials,O
40,are,O
40,cur,O
40,‐,O
40,rently,O
40,underway,O
40,.,O
40,The,O
40,World,ORGANIZATION
40,Health,ORGANIZATION
40,Organisation,ORGANIZATION
40,and,O
40,its,O
40,partners,O
40,have,O
40,launched,O
40,the,O
40,Solidarity,ORGANIZATION
40,trial,O
40,.2,O
40,a,O
40,large,O
40,international,O
40,study,O
40,to,O
40,compare,O
40,different,O
40,treatments,O
40,and,O
40,ensure,O
40,Therapeutic,O
40,Advances,O
40,in,O
40,Psychopharmacology,O
40,10,NUMBER
40,clear,O
40,evidence,O
40,of,O
40,which,O
40,treatments,O
40,are,O
40,most,O
40,effective,O
40,.,O
40,The,O
40,study,O
40,will,O
40,have,O
40,five,NUMBER
40,arms,O
40,:,O
40,standard,O
40,of,O
40,Oxford,CITY
40,have,O
40,launched,O
40,the,O
40,Recovery,O
40,trial,O
40,.3,O
40,which,O
40,will,O
40,be,O
40,testing,O
40,some,O
40,of,O
40,these,O
40,suggested,O
40,treatments,O
40,:,O
40,LPV,O
40,/,O
40,r,O
40,.,O
40,low,O
40,‐,O
40,dose,O
40,dexamethasone,O
40,.,O
40,HCLQ,O
40,and,O
40,inhaled,O
40,IFN,O
40,‐,O
40,beta1a,O
40,.,O
40,main,O
40,experimental,O
40,drugs,CRIMINAL_CHARGE
40,that,O
40,are,O
40,being,O
40,trialled,O
40,or,O
40,used,O
40,off,O
40,licence,O
40,to,O
40,treat,O
40,patients,O
40,with,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,For,O
40,each,O
40,drug,O
40,we,O
40,aimed,O
40,to,O
40,examine,O
40,trial,O
40,outcome,O
40,data,O
40,.,O
40,dosing,O
40,reg,O
40,‐,O
40,imens,O
40,.,O
40,adverse,O
40,effects,O
40,.,O
40,drug,O
40,interaction,O
40,potential,O
40,and,O
40,specific,O
40,drug,O
40,interactions,O
40,with,O
40,commonly,O
40,used,O
40,psychotropic,O
40,agents,O
40,in,O
40,the,O
40,United,COUNTRY
40,Kingdom,COUNTRY
40,(,O
40,UK,COUNTRY
40,),O
40,.,O
40,A,O
40,preliminary,O
40,search,O
40,identified,O
40,several,O
40,drugs,CRIMINAL_CHARGE
40,that,O
40,were,O
40,being,O
40,used,O
40,off,O
40,licence,O
40,around,O
40,the,O
40,world,O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,either,O
40,as,O
40,part,O
40,of,O
40,a,O
40,clinical,O
40,trial,O
40,or,O
40,on,O
40,a,O
40,compassionate,O
40,basis,O
40,.,O
40,For,O
40,each,O
40,potential,O
40,adverse,O
40,effects,O
40,.,O
40,We,O
40,then,O
40,used,O
40,the,O
40,following,O
40,drug,O
40,‐,O
40,interaction,O
40,databases,O
40,and,O
40,on,O
40,‐,O
40,line,O
40,re,O
40,‐,O
40,sources,O
40,to,O
40,identify,O
40,potential,O
40,drug,O
40,interactions,O
40,with,O
40,the,O
40,commonly,O
40,used,O
40,psychotropic,O
40,agents,O
40,in,O
40,the,O
40,UK,COUNTRY
40,:,O
40,Stockleys,O
40,Drug,O
40,Interactions,O
40,Checker,TITLE
40,.,O
40,human,O
40,immunodeficiency,O
40,virus,O
40,(,O
40,HIV,CAUSE_OF_DEATH
40,),O
40,drug,O
40,interactions,O
40,website,O
40,.,O
40,drug,O
40,interaction,O
40,checker,TITLE
40,.,O
40,the,O
40,Drugbank,O
40,and,O
40,the,O
40,Liverpool,ORGANIZATION
40,Drug,MISC
40,Interactions,MISC
40,Adverse,MISC
40,effects,O
40,.,O
40,ATV,O
40,can,O
40,cause,O
40,serious,O
40,.,O
40,lifethreatening,O
40,adverse,O
40,effects,O
40,.,O
40,including,O
40,heart,O
40,rhythm,O
40,abnormal,O
40,‐,O
40,ities,O
40,.,O
40,severe,O
40,rash,O
40,and,O
40,hepatic,O
40,disorders,O
40,.,O
40,as,O
40,well,O
40,as,O
40,life,O
40,‐,O
40,threat,O
40,‐,O
40,ening,O
40,drug,O
40,interactions,O
40,.,O
40,Drug,O
40,interactions,O
40,.,O
40,ATV,O
40,is,O
40,metabolised,O
40,principally,O
40,by,O
40,cytochrome,O
40,P450,O
40,(,O
40,CYP,O
40,),O
40,3A4,O
40,.,O
40,It,O
40,is,O
40,an,O
40,inhibitor,O
40,of,O
40,CYP3A4,O
40,and,O
40,a,O
40,weak,O
40,inhibitor,O
40,of,O
40,CYP2C8,O
40,.,O
40,When,O
40,co,O
40,‐,O
40,administered,O
40,with,O
40,ATV,O
40,.,O
40,increased,O
40,serum,O
40,levels,O
40,of,O
40,psychotropics,O
40,that,O
40,are,O
40,substrates,O
40,of,O
40,CYP3A4,O
40,can,O
40,occur,O
40,.,O
40,This,O
40,is,O
40,especially,O
40,true,O
40,for,O
40,lurasidone,O
40,.,O
40,que,O
40,‐,O
40,tiapine,O
40,and,O
40,ziprasidone,O
40,.,O
40,Their,O
40,levels,O
40,can,O
40,be,O
40,raised,O
40,significant,O
40,‐,O
40,ly,O
40,.,O
40,thus,O
40,increasing,O
40,the,O
40,risk,O
40,of,O
40,serious,O
40,adverse,O
40,effects,O
40,.,O
40,includ,O
40,‐,O
40,ing,O
40,prolongation,O
40,of,O
40,QTc,O
40,interval,O
40,.,O
40,These,O
40,combinations,O
40,should,O
40,be,O
40,avoided,O
40,if,O
40,possible,O
40,.,O
40,Other,O
40,CYP3A4,O
40,substrates,O
40,.,O
40,such,O
40,aripiprazole,O
40,.,O
40,clozapine,O
40,.,O
40,haloperidol,O
40,.,O
40,iloperidone,O
40,.,O
40,risperidone,O
40,and,O
40,zuclopen,O
40,‐,O
40,tixol,O
40,.,O
40,as,O
40,well,O
40,as,O
40,some,O
40,benzodiazepines,O
40,(,O
40,e.g.,O
40,clonazepam,O
40,.,O
40,diazepam,O
40,and,O
40,midazolam,O
40,),O
40,and,O
40,certain,O
40,antidepressants,O
40,(,O
40,e.g.,O
40,citalopram,O
40,.,O
40,es,O
40,‐,O
40,citalopram,O
40,.,O
40,clomipramine,O
40,.,O
40,imipramine,O
40,and,O
40,mirtazapine,O
40,.,O
40,amongst,O
40,others,O
40,),O
40,can,O
40,also,O
40,be,O
40,affected,O
40,in,O
40,the,O
40,same,O
40,way,O
40,when,O
40,co,O
40,‐,O
40,administered,O
40,with,O
40,ATV,O
40,and,O
40,may,O
40,require,O
40,dose,O
40,adjustments,O
40,or,O
40,monitoring,O
40,.,O
40,Carba,O
40,‐,O
40,mazepine,O
40,and,O
40,ATV,O
40,together,O
40,can,O
40,lead,O
40,to,O
40,increased,O
40,levels,O
40,of,O
40,carba,O
40,‐,O
40,mazepine,O
40,and,O
40,reduced,O
40,levels,O
40,of,O
40,ATV,O
40,and,O
40,this,O
40,combination,O
40,with,O
40,drugs,CRIMINAL_CHARGE
40,highly,O
40,dependent,O
40,on,O
40,CYP2C8,O
40,with,O
40,narrow,O
40,therapeutic,O
40,indices,O
40,is,O
40,not,O
40,recommended,O
40,(,O
40,no,O
40,psychotropic,O
40,meets,O
40,this,O
40,definition,O
40,),O
40,.,O
40,For,O
40,each,O
40,drug,O
40,identified,O
40,.,O
40,trial,O
40,outcome,O
40,data,O
40,.,O
40,dosing,O
40,regimens,O
40,.,O
40,ad,O
40,‐,O
40,verse,O
40,effects,O
40,and,O
40,drug,O
40,interaction,O
40,potential,O
40,are,O
40,reported,O
40,in,O
40,the,O
40,following,O
40,.,O
40,For,O
40,specific,O
40,drug,O
40,Dose,O
40,‐,O
40,related,O
40,asymptomatic,O
40,prolonga,O
40,‐,O
40,tions,O
40,in,O
40,the,O
40,PR,STATE_OR_PROVINCE
40,interval,O
40,with,O
40,ATV,O
40,have,O
40,been,O
40,observed,O
40,in,O
40,clinical,O
40,studies,O
40,.,O
40,Caution,O
40,should,O
40,be,O
40,used,O
40,when,O
40,prescribing,O
40,ATV,O
40,with,O
40,medici,O
40,‐,O
40,nal,O
40,products,O
40,that,O
40,have,O
40,the,O
40,potential,O
40,to,O
40,increase,O
40,the,O
40,QT,O
40,interval,O
40,;,O
40,a,O
40,potential,O
40,effect,O
40,of,O
40,many,O
40,antipsychotic,O
40,drugs,CRIMINAL_CHARGE
40,and,O
40,some,O
40,antide,O
40,‐,O
40,pressants,O
40,.,O
40,and,O
40,/,O
40,or,O
40,in,O
40,patients,O
40,with,O
40,pre,O
40,‐,O
40,existing,O
40,risk,O
40,factors,O
40,(,O
40,bradycardia,O
40,.,O
40,long,O
40,congenital,O
40,QT,O
40,.,O
40,electrolyte,O
40,imbalances,O
40,accord,O
40,‐,O
40,ing,O
40,to,O
40,the,O
40,Liverpool,ORGANIZATION
40,An,O
40,antiretroviral,O
40,medication,O
40,used,O
40,to,O
40,treat,O
40,and,O
40,prevent,O
40,the,O
40,human,O
40,immunodeficiency,O
40,virus,O
40,(,O
40,HIV,CAUSE_OF_DEATH
40,),O
40,AZI,O
40,is,O
40,a,O
40,macrolide,O
40,antibiotic,O
40,used,O
40,in,O
40,combination,O
40,with,O
40,HCLQ,O
40,(,O
40,for,O
40,dosage,O
40,information,O
40,see,O
40,HCLQ,O
40,),O
40,.,O
40,Dosage,O
40,information,O
40,.,O
40,Some,O
40,reports,O
40,have,O
40,emerged,O
40,where,O
40,the,O
40,following,O
40,regimen,O
40,was,O
40,used,O
40,for,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,pneumo,O
40,‐,O
40,nia,O
40,:,O
40,ATV,O
40,400,NUMBER
40,mg,O
40,daily,SET
40,for,O
40,2,DURATION
40,weeks,DURATION
40,in,O
40,combination,O
40,with,O
40,oseltamivir,O
40,150,NUMBER
40,mg,O
40,twice,O
40,daily,SET
40,+,O
40,/,O
40,methylprednisolone,O
40,40,NUMBER
40,mg,O
40,twice,O
40,data,O
40,for,O
40,its,O
40,use,O
40,to,O
40,support,O
40,this,O
40,.,O
40,Adverse,O
40,effects,O
40,.,O
40,Adverse,O
40,effects,O
40,include,O
40,gastrointestinal,O
40,effects,O
40,.,O
40,arrhythmias,O
40,.,O
40,QT,O
40,prolongation,O
40,and,O
40,hepat,O
40,‐,O
40,ic,O
40,disorders,O
40,.,O
40,Drug,O
40,interactions,O
40,.,O
40,AZI,O
40,does,O
40,not,O
40,interact,O
40,signifi,O
40,‐,O
40,cantly,O
40,with,O
40,the,O
40,hepatic,O
40,cytochrome,O
40,P450,O
40,system,O
40,.,O
40,It,O
40,is,O
40,not,O
40,be,O
40,‐,O
40,lieved,O
40,to,O
40,undergo,O
40,pharmacokinetic,O
40,D,O
40,Bishara,PERSON
40,.,O
40,C,O
40,Kalafatis,PERSON
40,et,O
40,al,O
40,.,O
40,Mood,O
40,stabilisers,O
40,Therapeutic,O
40,Advances,O
40,in,O
40,Psychopharmacology,O
40,10,NUMBER
40,Text,O
40,Legend,O
40,Potential,O
40,increase,O
40,exposure,O
40,of,O
40,drug,O
40,specified,O
40,Poten,O
40,‐,O
40,tial,O
40,decrease,O
40,exposure,O
40,of,O
40,drug,O
40,specified,O
40,No,O
40,significant,O
40,effect,O
40,on,O
40,drug,O
40,serum,O
40,levels,O
40,One,NUMBER
40,or,O
40,both,O
40,drugs,CRIMINAL_CHARGE
40,may,O
40,cause,O
40,QT,O
40,and,O
40,/,O
40,or,O
40,PR,STATE_OR_PROVINCE
40,pro,O
40,‐,O
40,longation,O
40,.,O
40,ECG,O
40,monitoring,O
40,advised,O
40,One,NUMBER
40,or,O
40,both,O
40,drugs,CRIMINAL_CHARGE
40,may,O
40,cause,O
40,bone,O
40,marrow,O
40,suppression,O
40,.,O
40,Monitor,O
40,FBC,O
40,One,NUMBER
40,or,O
40,more,O
40,drugs,CRIMINAL_CHARGE
40,may,O
40,reduce,O
40,seizure,O
40,threshold,O
40,.,O
40,Monitor,O
40,closely,O
40,.,O
40,Theoretical,O
40,drug,O
40,interaction,O
40,based,O
40,on,O
40,CYP,O
40,metabolism,O
40,.,O
40,however,O
40,no,O
40,specific,O
40,reports,O
40,These,O
40,drugs,CRIMINAL_CHARGE
40,should,O
40,not,O
40,be,O
40,co,O
40,‐,O
40,administered,O
40,Potential,O
40,interaction,O
40,which,O
40,may,O
40,re,O
40,‐,O
40,quire,O
40,a,O
40,dose,O
40,adjustment,O
40,or,O
40,close,O
40,monitoring,O
40,Potential,O
40,interaction,O
40,likely,O
40,to,O
40,be,O
40,of,O
40,weak,O
40,intensity,O
40,.,O
40,Additional,O
40,action,O
40,/,O
40,monitoring,O
40,or,O
40,dosage,O
40,adjustment,O
40,unlikely,O
40,to,O
40,be,O
40,required,O
40,No,O
40,clinically,O
40,signifi,O
40,‐,O
40,cant,O
40,interaction,O
40,expected,O
40,ATV,O
40,.,O
40,atazanavir,O
40,;,O
40,AZI,O
40,.,O
40,azithromycin,O
40,;,O
40,CLQ,O
40,.,O
40,chloroquine,O
40,;,O
40,CYP,O
40,.,O
40,cytochrome,O
40,P450,O
40,;,O
40,DIP,O
40,.,O
40,dipyridamole,O
40,;,O
40,ECG,O
40,.,O
40,electrocardiogram,O
40,;,O
40,FAM,O
40,.,O
40,famotidine,O
40,;,O
40,FAVI,O
40,.,O
40,favipiravir,O
40,;,O
40,FBC,O
40,.,O
40,full,O
40,blood,O
40,count,TITLE
40,;,O
40,HCLQ,O
40,.,O
40,hydroxychloroquine,O
40,;,O
40,LPV,O
40,/,O
40,r,O
40,.,O
40,lopinavir,O
40,/,O
40,riton,O
40,‐,O
40,avir,O
40,;,O
40,NITAZ,LOCATION
40,.,O
40,nitazoxanide,O
40,;,O
40,RDV,O
40,.,O
40,remdesivir,O
40,;,O
40,RBV,O
40,.,O
40,ribavirin,O
40,;,O
40,TCZ,O
40,.,O
40,tocilizumab,O
40,.,O
40,Dementia,CAUSE_OF_DEATH
40,drugs,CRIMINAL_CHARGE
40,D,PERSON
40,Bishara,PERSON
40,.,O
40,C,O
40,Kalafatis,PERSON
40,et,O
40,al,O
40,.,O
40,Ther,O
40,‐,O
40,apeutic,O
40,Advances,O
40,in,O
40,Psychopharmacology,O
40,10,NUMBER
40,drug,O
40,interactions,O
40,.,O
40,He,O
40,‐,O
40,patic,O
40,cytochrome,O
40,P450,O
40,induction,O
40,or,O
40,inactivation,O
40,via,O
40,cy,O
40,‐,O
40,tochromemetabolite,O
40,complex,O
40,does,O
40,not,O
40,occur,O
40,with,O
40,AZI,O
40,.,O
40,AZI,O
40,is,O
40,known,O
40,to,O
40,be,O
40,a,O
40,P,O
40,‐,O
40,glycoprotein,O
40,(,O
40,P,O
40,‐,O
40,gp,O
40,),O
40,inhibitor,O
40,and,O
40,.,O
40,if,O
40,co,O
40,‐,O
40,administered,O
40,with,O
40,P,O
40,‐,O
40,gp,O
40,substrates,O
40,(,O
40,e.g.,O
40,digoxin,O
40,.,O
40,colchicine,O
40,),O
40,.,O
40,it,O
40,has,O
40,been,O
40,re,O
40,‐,O
40,ported,O
40,to,O
40,result,O
40,in,O
40,increased,O
40,serum,O
40,levels,O
40,.,O
40,requiring,O
40,monitor,O
40,‐,O
40,ing,O
40,.10,NUMBER
40,Psychotropics,O
40,are,O
40,not,O
40,known,O
40,to,O
40,be,O
40,P,O
40,‐,O
40,gp,O
40,substrates,O
40,.,O
40,Whilst,O
40,pharmacokinetic,O
40,drug,O
40,interactions,O
40,are,O
40,not,O
40,a,O
40,problem,O
40,with,O
40,AZI,O
40,.,O
40,it,O
40,is,O
40,important,O
40,to,O
40,note,O
40,that,O
40,serious,O
40,pharmacodynamic,O
40,drug,O
40,interac,O
40,‐,O
40,tions,O
40,do,O
40,exist,O
40,when,O
40,co,O
40,‐,O
40,administered,O
40,with,O
40,psychotropic,O
40,agents,O
40,.,O
40,Since,O
40,QTc,O
40,prolongation,O
40,can,O
40,be,O
40,an,O
40,effect,O
40,exercised,O
40,when,O
40,used,O
40,to,O
40,‐,O
40,gether,O
40,as,O
40,the,O
40,risk,O
40,for,O
40,QTc,O
40,prolongation,O
40,is,O
40,further,O
40,increased,O
40,.,O
40,In,O
40,addition,O
40,.,O
40,some,O
40,psychotropics,O
40,are,O
40,known,O
40,to,O
40,cause,O
40,neutropenia,O
40,or,O
40,agranulocytosis,O
40,(,O
40,particularly,O
40,clozapine,O
40,and,O
40,carbamazepine,O
40,),O
40,.,O
40,which,O
40,is,O
40,also,O
40,a,O
40,potential,O
40,adverse,O
40,effect,O
40,of,O
40,AZI,O
40,.,O
40,Chloroquine,O
40,and,O
40,hy,O
40,‐,O
40,droxychloroquine,O
40,CLQ,O
40,and,O
40,HCLQ,ORGANIZATION
40,are,O
40,oral,O
40,drugs,CRIMINAL_CHARGE
40,that,O
40,have,O
40,been,O
40,used,O
40,for,O
40,the,O
40,prophylaxis,O
40,and,O
40,treatment,O
40,of,O
40,malaria,CAUSE_OF_DEATH
40,.,O
40,and,O
40,the,O
40,treatment,O
40,of,O
40,certain,O
40,inflammatory,O
40,conditions,O
40,such,O
40,as,O
40,rheumatoid,O
40,arthritis,O
40,and,O
40,systemic,O
40,lupus,CAUSE_OF_DEATH
40,erythematosus,CAUSE_OF_DEATH
40,.,O
40,Both,O
40,drugs,CRIMINAL_CHARGE
40,are,O
40,currently,DATE
40,being,O
40,trialled,O
40,in,O
40,patients,O
40,with,O
40,mild,O
40,‐,O
40,to,O
40,‐,O
40,severe,O
40,COVID,O
40,‐,O
40,19.2,NUMBER
40,HCQL,O
40,is,O
40,also,O
40,being,O
40,trialled,O
40,for,O
40,post,O
40,‐,O
40,exposure,O
40,prophylaxis,O
40,to,O
40,prevent,O
40,progres,O
40,‐,O
40,sion,O
40,to,O
40,symptomatic,O
40,disease,CAUSE_OF_DEATH
40,after,O
40,known,O
40,exposure,O
40,.,O
40,CLQ,O
40,is,O
40,being,O
40,trialled,O
40,for,O
40,prevention,O
40,of,O
40,COVID19,O
40,in,O
40,the,O
40,healthcare,O
40,setting,O
40,.11,NUMBER
40,Chloroquine,O
40,.,O
40,Use,O
40,of,O
40,CLQ,O
40,is,O
40,included,O
40,in,O
40,treatment,O
40,guidelines,O
40,from,O
40,Chinas,ORGANIZATION
40,National,ORGANIZATION
40,Health,ORGANIZATION
40,Commission,ORGANIZATION
40,and,O
40,was,O
40,reportedly,O
40,associated,O
40,with,O
40,reduced,O
40,progression,O
40,of,O
40,disease,CAUSE_OF_DEATH
40,and,O
40,decreased,O
40,China,COUNTRY
40,recom,O
40,‐,O
40,mends,O
40,CLQ,O
40,in,O
40,mild,O
40,to,O
40,severe,O
40,cases,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,as,O
40,it,O
40,may,O
40,improve,O
40,the,O
40,success,O
40,rate,O
40,of,O
40,treatment,O
40,.,O
40,shorten,O
40,hospital,O
40,stay,O
40,and,O
40,improve,O
40,patient,O
40,outcome,O
40,.12,NUMBER
40,Dosing,O
40,information,O
40,.,O
40,According,O
40,to,O
40,a,O
40,consensus,O
40,statement,O
40,from,O
40,a,O
40,multicentre,O
40,collaboration,O
40,group,O
40,diagnosed,O
40,as,O
40,having,O
40,mild,O
40,.,O
40,moderate,O
40,or,O
40,severe,O
40,cases,O
40,of,O
40,novel,O
40,coronavirus,O
40,pneu,O
40,‐,O
40,monia,O
40,and,O
40,without,O
40,contraindications,O
40,to,O
40,CLQ,O
40,.12,NUMBER
40,Hydroxychloroquine,O
40,.,O
40,There,O
40,is,O
40,a,O
40,considerable,O
40,interest,O
40,for,O
40,the,O
40,use,O
40,of,O
40,HCLQ,O
40,to,O
40,treat,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,disease,CAUSE_OF_DEATH
40,;,O
40,however,O
40,.,O
40,significant,O
40,methodological,O
40,limitations,O
40,do,O
40,not,O
40,allow,O
40,for,O
40,definitive,O
40,conclusions,O
40,.,O
40,A,O
40,small,O
40,randomised,O
40,con,O
40,‐,O
40,trolled,O
40,trial,O
40,(,O
40,20,NUMBER
40,patients,O
40,),O
40,found,O
40,that,O
40,HCLQ,O
40,(,O
40,with,O
40,or,O
40,without,O
40,AZI,O
40,),O
40,was,O
40,efficient,O
40,in,O
40,reducing,O
40,viral,O
40,nasopharyngeal,O
40,carriage,O
40,of,O
40,SARS,O
40,‐,O
40,CoV,O
40,‐,O
40,2,NUMBER
40,in,O
40,36,DURATION
40,days,DURATION
40,in,O
40,most,O
40,patients,O
40,.,O
40,The,O
40,addition,O
40,of,O
40,AZI,O
40,(,O
40,to,O
40,six,NUMBER
40,patients,O
40,),O
40,was,O
40,thought,O
40,to,O
40,be,O
40,synergistic,O
40,and,O
40,the,O
40,combination,O
40,was,O
40,found,O
40,to,O
40,be,O
40,significantly,O
40,more,O
40,efficient,O
40,for,O
40,virus,O
40,elimination13,O
40,;,O
40,however,O
40,the,O
40,sample,O
40,was,O
40,small,O
40,.,O
40,the,O
40,majority,O
40,of,O
40,patients,O
40,presented,O
40,with,O
40,mild,O
40,symptoms,O
40,and,O
40,the,O
40,suffered,O
40,from,O
40,other,O
40,significant,O
40,co,O
40,‐,O
40,morbidities,O
40,.,O
40,A,O
40,similar,O
40,combination,O
40,trial,O
40,of,O
40,HCLQ,O
40,and,O
40,AZI,O
40,in,O
40,11,NUMBER
40,participants,O
40,did,O
40,not,O
40,replicate,O
40,the,O
40,previously,DATE
40,mentioned,O
40,results,O
40,.,O
40,Crucially,O
40,.,O
40,8,NUMBER
40,out,O
40,of,O
40,11,NUMBER
40,had,O
40,significant,O
40,comorbidities,O
40,associated,O
40,with,O
40,poor,O
40,outcomes,O
40,.14,NUMBER
40,Another,O
40,randomised,O
40,open,O
40,‐,O
40,label,O
40,study,O
40,in,O
40,30,NUMBER
40,Chinese,NATIONALITY
40,participants,O
40,(,O
40,1:1,NUMBER
40,randomisation,O
40,),O
40,did,O
40,not,O
40,offer,O
40,conclusive,O
40,results,O
40,on,O
40,the,O
40,efficacy,O
40,of,O
40,HCLQ,O
40,.15,NUMBER
40,The,O
40,only,O
40,publicly,O
40,available,O
40,randomised,O
40,control,O
40,trial,O
40,of,O
40,HCLQ,O
40,in,O
40,62,NUMBER
40,Chinese,NATIONALITY
40,participants,O
40,re,O
40,‐,O
40,mains,O
40,HCLQ,O
40,/,O
40,AZI,O
40,combination,O
40,is,O
40,associated,O
40,with,O
40,high,O
40,risk,O
40,of,O
40,QTc,O
40,prolongation,O
40,.,O
40,In,O
40,84,NUMBER
40,adult,O
40,patients,O
40,with,O
40,SARS,O
40,‐,O
40,CoV,O
40,‐,O
40,2,NUMBER
40,infection,CAUSE_OF_DEATH
40,treated,O
40,with,O
40,this,O
40,combination,O
40,.,O
40,QTc,O
40,was,O
40,significantly,O
40,prolonged,O
40,from,O
40,baseline,O
40,between,O
40,days,DURATION
40,3,NUMBER
40,and,O
40,4,NUMBER
40,.,O
40,In,O
40,30,PERCENT
40,%,PERCENT
40,of,O
40,patients,O
40,QTc,O
40,in,O
40,‐,O
40,creased,O
40,by,O
40,greater,O
40,than,O
40,40,NUMBER
40,ms.,O
40,In,O
40,11,PERCENT
40,%,PERCENT
40,of,O
40,patients,O
40,QTc,O
40,increased,O
40,to,O
40,>,O
40,500,NUMBER
40,ms,O
40,.,O
40,representing,O
40,a,O
40,high,O
40,risk,O
40,group,O
40,for,O
40,arrhythmia,O
40,.,O
40,The,O
40,development,O
40,of,O
40,acute,O
40,renal,CAUSE_OF_DEATH
40,failure,CAUSE_OF_DEATH
40,but,O
40,not,O
40,baseline,O
40,QTc,O
40,was,O
40,a,O
40,strong,O
40,predictor,O
40,of,O
40,extreme,O
40,QTc,O
40,prolongation,O
40,.17,NUMBER
40,Dosing,O
40,informa,O
40,‐,O
40,tion,O
40,.,O
40,HCLQ,O
40,200,NUMBER
40,mg,O
40,three,NUMBER
40,times,O
40,a,DURATION
40,day,DURATION
40,for,O
40,10,DURATION
40,days,DURATION
40,.,O
40,(,O
40,Recent,O
40,studies,O
40,linking,O
40,HCLQ,O
40,treatment,O
40,to,O
40,viral,O
40,load,O
40,reduction,O
40,in,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,pa,O
40,‐,O
40,tients,O
40,did,O
40,so,O
40,with,O
40,higher,O
40,dose,O
40,treatment,O
40,.,O
40,using,O
40,either,O
40,a,O
40,600,NUMBER
40,mg,O
40,daily,SET
40,dose,O
40,or,O
40,1000,DATE
40,mg,O
40,daily,SET
40,dose,O
40,),O
40,.18,NUMBER
40,AZI,O
40,dosage,O
40,used,O
40,was,O
40,(,O
40,500,NUMBER
40,mg,O
40,daily,SET
40,day,DURATION
40,1,NUMBER
40,followed,O
40,by,O
40,250,NUMBER
40,mg,O
40,per,O
40,day,DURATION
40,.,O
40,the,DURATION
40,next,DURATION
40,4,DURATION
40,days,DURATION
40,),O
40,.,O
40,It,O
40,has,O
40,been,O
40,suggested,O
40,that,O
40,early,O
40,treatment,O
40,is,O
40,important,O
40,.3,NUMBER
40,D,O
40,Bishara,PERSON
40,.,O
40,C,O
40,Kalafatis,PERSON
40,et,O
40,al,O
40,.,O
40,Adverse,O
40,effects,O
40,for,O
40,CLQ,O
40,/,O
40,HCLQ,O
40,.,O
40,Gastrointestinal,O
40,effects,O
40,.,O
40,such,O
40,as,O
40,vomiting,O
40,and,O
40,diarrhoea,CAUSE_OF_DEATH
40,.,O
40,are,O
40,the,O
40,most,O
40,common,O
40,ad,O
40,‐,O
40,verse,O
40,effects,O
40,of,O
40,these,O
40,two,NUMBER
40,drugs,CRIMINAL_CHARGE
40,.,O
40,Patients,O
40,with,O
40,long,O
40,‐,O
40,term,O
40,expo,O
40,‐,O
40,sure,O
40,to,O
40,CLQ,O
40,suffer,O
40,from,O
40,severe,O
40,side,O
40,effects,O
40,such,O
40,as,O
40,retinopathy,O
40,and,O
40,cardiotoxic,O
40,effects,O
40,.19,NUMBER
40,CLQ,O
40,and,O
40,HCLQ,O
40,have,O
40,been,O
40,shown,O
40,to,O
40,pro,O
40,‐,O
40,long,O
40,the,O
40,QTc,O
40,interval,O
40,in,O
40,some,O
40,patients,O
40,and,O
40,should,O
40,therefore,O
40,be,O
40,used,O
40,with,O
40,caution,O
40,in,O
40,patients,O
40,receiving,O
40,concomitant,O
40,drugs,CRIMINAL_CHARGE
40,known,O
40,to,O
40,prolong,O
40,the,O
40,QT,O
40,interval,O
40,or,O
40,where,O
40,a,O
40,drug,O
40,interaction,O
40,may,O
40,in,O
40,‐,O
40,crease,O
40,CLQ,O
40,or,O
40,HCLQ,O
40,exposure,O
40,(,O
40,see,O
40,drug,O
40,interactions,O
40,in,O
40,the,O
40,follow,O
40,‐,O
40,ing,O
40,),O
40,.,O
40,Electrocardiogram,O
40,(,O
40,ECG,O
40,),O
40,monitoring,O
40,would,O
40,be,O
40,recommended,O
40,in,O
40,these,O
40,instances,O
40,.9,NUMBER
40,Caution,O
40,is,O
40,also,O
40,advised,O
40,when,O
40,considering,O
40,these,O
40,drugs,CRIMINAL_CHARGE
40,in,O
40,patients,O
40,with,O
40,chronic,O
40,medical,O
40,conditions,O
40,(,O
40,e.g.,O
40,renal,O
40,failure,O
40,.,O
40,hepatic,O
40,disease,CAUSE_OF_DEATH
40,),O
40,.,O
40,HCLQ,ORGANIZATION
40,has,O
40,similar,O
40,therapeutic,O
40,effects,O
40,to,O
40,CLQ,O
40,.,O
40,but,O
40,less,O
40,severe,O
40,adverse,O
40,effects,O
40,.,O
40,It,O
40,is,O
40,considered,O
40,safe,O
40,in,O
40,pregnancy,O
40,and,O
40,is,O
40,more,O
40,readily,O
40,available,O
40,in,O
40,some,O
40,countries,O
40,.,O
40,More,O
40,importantly,O
40,.,O
40,the,O
40,maximum,O
40,dose,O
40,for,O
40,HCLQ,O
40,is,O
40,1200,NUMBER
40,mg,O
40,.,O
40,which,O
40,has,O
40,an,O
40,antiviral,O
40,effect,O
40,equivalent,O
40,to,O
40,750,NUMBER
40,mg,O
40,CLQ,O
40,(,O
40,for,O
40,which,O
40,the,O
40,maximum,O
40,tolerable,O
40,dose,O
40,can,O
40,be,O
40,500,NUMBER
40,mg,O
40,),O
40,.,O
40,Hence,O
40,.,O
40,HCLQ,O
40,can,O
40,be,O
40,administered,O
40,at,O
40,a,O
40,higher,O
40,equivalent,O
40,dosage,O
40,and,O
40,may,O
40,therefore,O
40,achieve,O
40,more,O
40,pow,O
40,‐,O
40,erful,O
40,antiviral,O
40,effect,O
40,.20,NUMBER
40,The,O
40,United,COUNTRY
40,States,COUNTRY
40,Food,O
40,and,O
40,Drug,O
40,Admin,O
40,‐,O
40,istration,O
40,(,O
40,FDA,ORGANIZATION
40,),O
40,has,O
40,recently,DATE
40,issued,O
40,a,O
40,warning,O
40,that,O
40,CLQ,O
40,and,O
40,HCLQ,O
40,should,O
40,be,O
40,used,O
40,for,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,only,O
40,when,O
40,patients,O
40,can,O
40,be,O
40,appropri,O
40,‐,O
40,ately,O
40,monitored,O
40,in,O
40,the,O
40,hospital,O
40,setting,O
40,or,O
40,are,O
40,enrolled,O
40,in,O
40,a,O
40,clinical,O
40,trial,O
40,with,O
40,appropriate,O
40,screening,O
40,and,O
40,monitoring,O
40,.,O
40,use,O
40,for,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,outside,O
40,the,O
40,hospital,O
40,setting,O
40,after,O
40,reports,O
40,of,O
40,QT,O
40,in,O
40,‐,O
40,terval,O
40,prolongation,O
40,and,O
40,ventricular,O
40,tachycardia,O
40,.21,NUMBER
40,Drug,O
40,interac,O
40,‐,O
40,tions,O
40,.,O
40,CLQ,O
40,and,O
40,HCLQ,O
40,undergo,O
40,CYP,O
40,‐,O
40,mediated,O
40,metabolism,O
40,by,O
40,CYPs,O
40,2C8,O
40,.,O
40,3A4,O
40,and,O
40,2D6,O
40,.,O
40,Co,O
40,‐,O
40,administration,O
40,with,O
40,inhibitors,O
40,and,O
40,inducers,O
40,of,O
40,these,O
40,isoenzymes,O
40,may,O
40,increase,O
40,or,O
40,decrease,O
40,exposure,O
40,to,O
40,them,O
40,.,O
40,re,O
40,‐,O
40,spectively,O
40,.,O
40,and,O
40,dose,O
40,changes,O
40,or,O
40,additional,O
40,monitoring,O
40,could,O
40,be,O
40,considered,O
40,.,O
40,Fluoxetine,O
40,and,O
40,paroxetine,O
40,are,O
40,inhibitors,O
40,of,O
40,both,O
40,CYP3A4,O
40,and,O
40,CYP2D6,O
40,and,O
40,can,O
40,therefore,O
40,lead,O
40,to,O
40,increased,O
40,levels,O
40,of,O
40,CLQ,O
40,and,O
40,HCLQ,O
40,.,O
40,in,O
40,turn,O
40,increasing,O
40,the,O
40,risk,O
40,of,O
40,QTc,O
40,prolongation,O
40,.,O
40,Other,O
40,psychotropics,O
40,that,O
40,are,O
40,important,O
40,inhibitors,O
40,of,O
40,CYP2D6,O
40,in,O
40,‐,O
40,clude,O
40,amitriptyline,O
40,.,O
40,bupropion,O
40,and,O
40,duloxetine,O
40,.,O
40,Carbamazepine,O
40,in,O
40,‐,O
40,duces,O
40,CYP3A4,O
40,and,O
40,can,O
40,lead,O
40,to,O
40,reduced,O
40,levels,O
40,of,O
40,CLQ,O
40,and,O
40,HCLQ,O
40,.,O
40,CLQ,O
40,and,O
40,HCLQ,O
40,are,O
40,moderate,O
40,inhibitors,O
40,of,O
40,CYP2D6,O
40,and,O
40,P,O
40,‐,O
40,gp,O
40,.,O
40,and,O
40,caution,O
40,may,O
40,be,O
40,required,O
40,when,O
40,co,O
40,‐,O
40,administering,O
40,medication,O
40,with,O
40,a,O
40,narrow,O
40,therapeutic,O
40,index,O
40,that,O
40,are,O
40,metabolised,O
40,or,O
40,transported,O
40,by,O
40,these,O
40,pathways,O
40,.9,NUMBER
40,Psychotropics,O
40,that,O
40,are,O
40,substrates,O
40,of,O
40,CYP2D6,O
40,and,O
40,that,O
40,will,O
40,undergo,O
40,reduced,O
40,metabolism,O
40,and,O
40,have,O
40,increased,O
40,levels,O
40,when,O
40,co,O
40,‐,O
40,administered,O
40,with,O
40,these,O
40,drugs,CRIMINAL_CHARGE
40,include,O
40,aripiprazole,O
40,.,O
40,chlorpro,O
40,‐,O
40,mazine,O
40,.,O
40,iloperidone,O
40,.,O
40,olanzapine,O
40,.,O
40,risperidone,O
40,.,O
40,zuclopentixol,O
40,.,O
40,clomipramine,O
40,.,O
40,The,O
40,following,O
40,pharmacodynamic,O
40,drug,O
40,interactions,O
40,should,O
40,be,O
40,considered,O
40,carefully,O
40,.,O
40,Since,O
40,CLQ,O
40,and,O
40,HCLQ,O
40,have,O
40,been,O
40,shown,O
40,to,O
40,prolong,O
40,QTc,O
40,interval,O
40,.,O
40,caution,O
40,should,O
40,be,O
40,used,O
40,when,O
40,co,O
40,‐,O
40,ad,O
40,‐,O
40,ministered,O
40,with,O
40,most,O
40,antipsychotics,O
40,and,O
40,some,O
40,antidepressant,O
40,drugs,CRIMINAL_CHARGE
40,.,O
40,such,O
40,as,O
40,tricyclic,O
40,antidepressants,O
40,.,O
40,c,O
40,italopram,O
40,.,O
40,escitalo,O
40,‐,O
40,pram,O
40,.,O
40,venlafaxine,O
40,.,O
40,trazodone,O
40,and,O
40,lithium,O
40,addition,O
40,.,O
40,CLQ,O
40,and,O
40,HCLQ,O
40,have,O
40,been,O
40,reported,O
40,to,O
40,cause,O
40,bone,O
40,marrow,O
40,failure,O
40,.,O
40,neutropenia,O
40,and,O
40,agranulocytosis,O
40,Therefore,O
40,.,O
40,co,O
40,‐,O
40,administration,O
40,with,O
40,carbamazepine,O
40,should,O
40,be,O
40,avoided,O
40,.,O
40,and,O
40,if,O
40,used,O
40,with,O
40,clozapine,O
40,.,O
40,cautious,O
40,use,O
40,and,O
40,close,O
40,monitoring,O
40,are,O
40,advised,O
40,.,O
40,Furthermore,O
40,.,O
40,CLQ,O
40,and,O
40,HCLQ,O
40,may,O
40,lower,O
40,the,O
40,convulsive,O
40,threshold,O
40,and,O
40,thus,O
40,antagonise,O
40,the,O
40,actions,O
40,of,O
40,antiepileptics,O
40,such,O
40,as,O
40,c,O
40,arbamazepine,O
40,.,O
40,lamotrigine,O
40,or,O
40,sodium,O
40,val,O
40,‐,O
40,proate,O
40,.,O
40,They,O
40,should,O
40,also,O
40,be,O
40,used,O
40,with,O
40,caution,O
40,with,O
40,bupropion,O
40,.,O
40,which,O
40,can,O
40,also,O
40,reduce,O
40,seizure,O
40,threshold,O
40,.,O
40,Dipyridamole,O
40,(,O
40,DIP,O
40,),O
40,is,O
40,an,O
40,antiplatelet,O
40,agent,O
40,and,O
40,acts,O
40,as,O
40,a,O
40,phosphodiesterase,O
40,(,O
40,PDE,O
40,),O
40,in,O
40,‐,O
40,hibitor,O
40,that,O
40,increases,O
40,intracellular,O
40,cAMP,O
40,/,O
40,cGMP,O
40,.,O
40,Apart,O
40,from,O
40,the,O
40,well,O
40,‐,O
40,known,O
40,antiplatelet,O
40,function,O
40,.,O
40,DIP,O
40,may,O
40,provide,O
40,potential,O
40,ther,O
40,‐,O
40,apeutic,O
40,benefits,O
40,to,O
40,patients,O
40,clinical,O
40,trials,O
40,conducted,O
40,in,O
40,China,COUNTRY
40,.,O
40,have,O
40,demonstrated,O
40,that,O
40,it,O
40,has,O
40,a,O
40,broad,O
40,spectrum,O
40,antiviral,O
40,activi,O
40,‐,O
40,ty,O
40,.,O
40,particularly,O
40,efficacious,O
40,against,O
40,positivestranded,O
40,RNA,O
40,virus,O
40,‐,O
40,es,O
40,;,O
40,it,O
40,suppresses,O
40,inflammation,O
40,and,O
40,promotes,O
40,mucosal,O
40,healing,O
40,.,O
40,and,O
40,.,O
40,as,O
40,a,O
40,pan,O
40,‐,O
40,PDE,O
40,inhibitor,O
40,.,O
40,it,O
40,may,O
40,also,O
40,prevent,O
40,acute,O
40,injury,O
40,and,O
40,pro,O
40,‐,O
40,gressive,O
40,fibrosis,O
40,of,O
40,the,O
40,lung,O
40,.,O
40,heart,O
40,.,O
40,liver,O
40,and,O
40,kidneys,O
40,.22,NUMBER
40,COVID,O
40,‐,O
40,19,NUMBER
40,infection,CAUSE_OF_DEATH
40,can,O
40,cause,O
40,acute,O
40,respiratory,O
40,distress,O
40,syndrome,O
40,.,O
40,hypercoagulability,O
40,.,O
40,hypertension,CAUSE_OF_DEATH
40,and,O
40,multiorgan,O
40,dysfunction,O
40,.,O
40,In,O
40,an,O
40,analysis,O
40,of,O
40,a,O
40,randomly,O
40,collected,O
40,cohort,O
40,of,O
40,124,NUMBER
40,patients,O
40,with,O
40,the,O
40,disease,CAUSE_OF_DEATH
40,.,O
40,researchers,O
40,from,O
40,China,COUNTRY
40,found,O
40,that,O
40,hypercoagulability,O
40,as,O
40,Therapeutic,O
40,Advances,O
40,in,O
40,Psychopharmacology,O
40,10,NUMBER
40,indicated,O
40,by,O
40,el,O
40,‐,O
40,evated,O
40,concentrations,O
40,of,O
40,D,O
40,‐,O
40,dimers,O
40,was,O
40,associated,O
40,with,O
40,disease,CAUSE_OF_DEATH
40,severity,O
40,.,O
40,They,O
40,identified,O
40,DIP,O
40,.,O
40,which,O
40,suppressed,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,replica,O
40,‐,O
40,tion,O
40,in,O
40,vitro,O
40,.,O
40,22,NUMBER
40,Dosage,O
40,information,O
40,.,O
40,The,O
40,daily,SET
40,treatment,O
40,proto,O
40,‐,O
40,col,O
40,comprises,O
40,oral,O
40,DIP,O
40,150,NUMBER
40,mg,O
40,in,O
40,three,NUMBER
40,separate,O
40,doses,O
40,for,O
40,14,NUMBER
40,con,O
40,‐,O
40,secutive,O
40,days,DURATION
40,.,O
40,Adverse,O
40,effects,O
40,.,O
40,Gastrointestinal,O
40,adverse,O
40,effects,O
40,are,O
40,common,O
40,with,O
40,DIP,O
40,.,O
40,and,O
40,thrombocytopenia,O
40,and,O
40,tachycardia,O
40,have,O
40,been,O
40,reported,O
40,although,O
40,frequency,O
40,is,O
40,not,O
40,known,O
40,.23,NUMBER
40,Because,O
40,DIP,O
40,is,O
40,a,O
40,PDE,O
40,inhibitor,O
40,and,O
40,can,O
40,exacerbate,O
40,bronchospasm,O
40,(,O
40,frequency,O
40,not,O
40,known,O
40,),O
40,.,O
40,particularly,O
40,in,O
40,patients,O
40,with,O
40,reactive,O
40,airway,O
40,disease,CAUSE_OF_DEATH
40,and,O
40,/,O
40,or,O
40,chronic,CAUSE_OF_DEATH
40,obstructive,CAUSE_OF_DEATH
40,pulmonary,CAUSE_OF_DEATH
40,disease,CAUSE_OF_DEATH
40,(,O
40,COPD,O
40,),O
40,.,O
40,Therapy,O
40,with,O
40,DIP,O
40,is,O
40,contraindicated,O
40,in,O
40,patients,O
40,with,O
40,active,O
40,wheezing,O
40,and,O
40,should,O
40,be,O
40,administered,O
40,cautiously,O
40,in,O
40,patients,O
40,with,O
40,asthma,CAUSE_OF_DEATH
40,or,O
40,COPD,O
40,and,O
40,therefore,O
40,in,O
40,COVID19,O
40,patients,O
40,as,O
40,well,O
40,.24,NUMBER
40,Drug,O
40,interactions,O
40,.,O
40,Metabolism,O
40,of,O
40,DIP,O
40,occurs,O
40,in,O
40,the,O
40,liver,O
40,.,O
40,DIP,O
40,is,O
40,metabolized,O
40,by,O
40,con,O
40,‐,O
40,jugation,O
40,with,O
40,glucuronic,O
40,acid,O
40,to,O
40,form,O
40,mainly,O
40,a,O
40,monoglucuronide,O
40,and,O
40,only,O
40,small,O
40,amounts,O
40,of,O
40,diglucuronide,O
40,.,O
40,In,O
40,plasma,O
40,.,O
40,about,O
40,80,PERCENT
40,%,PERCENT
40,of,O
40,the,O
40,total,O
40,amount,O
40,is,O
40,parent,O
40,compound,O
40,.,O
40,20,PERCENT
40,%,PERCENT
40,of,O
40,the,O
40,total,O
40,amount,O
40,is,O
40,monoglucuronide,O
40,with,O
40,oral,O
40,administration,O
40,.23,NUMBER
40,The,O
40,bleeding,O
40,risk,O
40,as,O
40,‐,O
40,sociated,O
40,with,O
40,DIP,O
40,might,O
40,be,O
40,further,O
40,increased,O
40,by,O
40,the,O
40,concurrent,O
40,use,O
40,of,O
40,a,O
40,serotonin,O
40,reuptake,O
40,inhibitors,O
40,(,O
40,SRIs,O
40,),O
40,.,O
40,Serotonin,O
40,release,O
40,by,O
40,platelets,O
40,plays,O
40,an,O
40,important,O
40,role,O
40,in,O
40,have,O
40,documented,O
40,the,O
40,oc,O
40,‐,O
40,currence,O
40,of,O
40,bleeding,O
40,episodes,O
40,in,O
40,patients,O
40,treated,O
40,with,O
40,psy,O
40,‐,O
40,chotropic,O
40,agents,O
40,that,O
40,interfere,O
40,with,O
40,serotonin,O
40,reuptake,O
40,.,O
40,Bleeding,O
40,events,O
40,related,O
40,to,O
40,SRIs,O
40,have,O
40,ranged,O
40,from,O
40,ecchymosis,O
40,.,O
40,haematoma,O
40,.,O
40,epistaxis,O
40,and,O
40,petechiae,O
40,to,O
40,life,O
40,‐,O
40,threatening,O
40,haemorrhages,O
40,.25,NUMBER
40,Therefore,O
40,.,O
40,caution,O
40,should,O
40,be,O
40,used,O
40,with,O
40,citalopram,O
40,.,O
40,escitalopram,O
40,.,O
40,fluoxetine,O
40,.,O
40,paroxetine,O
40,and,O
40,sertraline,O
40,as,O
40,well,O
40,as,O
40,clomipramine,O
40,.,O
40,duloxetine,O
40,.,O
40,venlafaxine,O
40,and,O
40,vortioxetine,O
40,.,O
40,Monitor,O
40,closely,O
40,for,O
40,bleeding,O
40,.,O
40,Gastroprotection,O
40,(,O
40,such,O
40,as,O
40,a,O
40,proton,O
40,pump,O
40,inhibitor,O
40,),O
40,in,O
40,those,O
40,at,O
40,high,O
40,risk,O
40,of,O
40,gastrointestinal,O
40,bleeding,O
40,(,O
40,e.g.,O
40,history,O
40,of,O
40,gastrointestinal,O
40,bleeding,O
40,.,O
40,the,O
40,elderly,O
40,),O
40,should,O
40,be,O
40,considered,O
40,.4,NUMBER
40,DIP,O
40,may,O
40,also,O
40,increase,O
40,the,O
40,hypotensive,O
40,effect,O
40,of,O
40,psychotropic,O
40,drugs,CRIMINAL_CHARGE
40,that,O
40,reduce,O
40,blood,O
40,pressure,O
40,and,O
40,may,O
40,counteract,O
40,the,O
40,anti,O
40,‐,O
40,cholinesterase,O
40,effect,O
40,of,O
40,cholinesterase,O
40,inhibitors,O
40,.23.26,NUMBER
40,Famoti,O
40,‐,O
40,dine,O
40,(,O
40,FAM,O
40,),O
40,is,O
40,a,O
40,H2,O
40,antagonist,O
40,use,O
40,to,O
40,treat,O
40,heartburn,O
40,.,O
40,ulcers,O
40,and,O
40,ZollingerEllison,O
40,syndrome,O
40,.,O
40,Earlier,O
40,in,O
40,the,O
40,outbreak,O
40,.,O
40,doctors,O
40,who,O
40,worked,O
40,with,O
40,coronavirus,O
40,patients,O
40,in,O
40,Wuhan,CITY
40,.,O
40,China,COUNTRY
40,discovered,O
40,that,O
40,.,O
40,although,O
40,one,NUMBER
40,in,O
40,five,NUMBER
40,COVID,O
40,‐,DATE
40,19,DATE
40,patients,O
40,over,O
40,the,O
40,age,O
40,of,O
40,80,NUMBER
40,died,O
40,.,O
40,many,O
40,of,O
40,those,O
40,who,O
40,survived,O
40,had,O
40,been,O
40,taking,O
40,the,O
40,heartburn,O
40,medica,O
40,‐,O
40,tion,O
40,FAM,O
40,.,O
40,In,O
40,fact,O
40,.,O
40,hospitalized,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,patients,O
40,on,O
40,FAM,O
40,appeared,O
40,to,O
40,be,O
40,dying,O
40,at,O
40,a,O
40,rate,O
40,of,O
40,about,O
40,14,PERCENT
40,%,PERCENT
40,compared,O
40,with,O
40,27,PERCENT
40,%,PERCENT
40,for,O
40,those,O
40,not,O
40,on,O
40,the,O
40,drug,O
40,.,O
40,and,O
40,.,O
40,although,O
40,the,O
40,analysis,O
40,was,O
40,crude,O
40,.,O
40,the,O
40,result,O
40,was,O
40,not,O
40,statistically,O
40,significant,O
40,and,O
40,studies,O
40,on,O
40,the,O
40,Chinese,NATIONALITY
40,pa,O
40,‐,O
40,tients,O
40,have,O
40,to,O
40,encourage,O
40,US,COUNTRY
40,scientists,O
40,to,O
40,explore,O
40,FAMs,O
40,As,O
40,part,O
40,of,O
40,a,O
40,clinical,O
40,trial,O
40,.,O
40,patients,O
40,at,O
40,New,STATE_OR_PROVINCE
40,York,STATE_OR_PROVINCE
40,Citys,LOCATION
40,Northwell,LOCATION
40,Health,LOCATION
40,have,O
40,been,O
40,receiving,O
40,FAM,O
40,intravenously,O
40,.,O
40,at,O
40,a,O
40,dose,O
40,nine,NUMBER
40,times,O
40,greater,O
40,than,O
40,what,O
40,people,O
40,typically,O
40,take,O
40,for,O
40,heartburn,O
40,(,O
40,specific,O
40,dosing,O
40,details,O
40,are,O
40,not,O
40,available,O
40,),O
40,.,O
40,The,O
40,randomised,O
40,.,O
40,double,O
40,‐,O
40,blind,O
40,trial,O
40,.,O
40,which,O
40,began,O
40,on,O
40,7,DATE
40,April,DATE
40,2020,DATE
40,.,O
40,has,O
40,enrolled,O
40,187,NUMBER
40,participants,O
40,to,O
40,date,O
40,.,O
40,but,O
40,expects,O
40,to,O
40,expand,O
40,to,O
40,a,O
40,total,O
40,of,O
40,1174,DATE
40,individuals,O
40,in,O
40,critical,O
40,status,O
40,.,O
40,including,O
40,many,O
40,on,O
40,Adverse,MISC
40,effects,O
40,.,O
40,ECG,O
40,changes,O
40,are,O
40,seen,O
40,;,O
40,prolonged,O
40,QT,O
40,interval,O
40,has,O
40,been,O
40,reported,O
40,in,O
40,patients,O
40,with,O
40,moderate,O
40,‐,O
40,to,O
40,‐,O
40,severe,O
40,renal,O
40,impairment,O
40,.,O
40,The,O
40,FDA,ORGANIZATION
40,has,O
40,received,O
40,reports,O
40,of,O
40,torsades,O
40,de,O
40,pointes,O
40,occurring,O
40,with,O
40,FAM,O
40,.,O
40,There,O
40,have,O
40,al,O
40,‐,O
40,so,O
40,been,O
40,rare,O
40,reports,O
40,of,O
40,seizures,O
40,.,O
40,thrombocytopenia,O
40,.,O
40,leukopenia,O
40,.,O
40,agranulocytosis,O
40,.,O
40,pancytopenia,O
40,intrahepatic,O
40,cholestasis,O
40,.,O
40,jaundice,CAUSE_OF_DEATH
40,and,O
40,increased,O
40,liver,O
40,enzyme,O
40,abnormalities,O
40,.,O
40,In,O
40,addition,O
40,.,O
40,it,O
40,can,O
40,very,O
40,rarely,O
40,cause,O
40,psychiatric,O
40,effects,O
40,such,O
40,as,O
40,depression,O
40,.,O
40,anxiety,O
40,and,O
40,Drug,O
40,interactions,O
40,.,O
40,FAM,O
40,is,O
40,considered,O
40,a,O
40,weak,O
40,CYP1A2,O
40,inhibitor,O
40,and,O
40,may,O
40,lead,O
40,to,O
40,substantial,O
40,increases,O
40,in,O
40,blood,O
40,concentrations,O
40,of,O
40,CYP1A2,O
40,substrates,O
40,.,O
40,Whilst,O
40,there,O
40,are,O
40,no,O
40,reports,O
40,.,O
40,theoretically,O
40,.,O
40,co,O
40,‐,O
40,administration,O
40,can,O
40,lead,O
40,to,O
40,increased,O
40,levels,O
40,of,O
40,clozapine,O
40,.,O
40,olanzapine,O
40,and,O
40,agomelatine,O
40,as,O
40,they,O
40,are,O
40,predominantly,O
40,CYP,O
40,1A2,O
40,sub,O
40,‐,O
40,strates,O
40,.29,NUMBER
40,FAM,O
40,may,O
40,cause,O
40,QTc,O
40,prolongation,O
40,.,O
40,Theoretically,O
40,.,O
40,coad,O
40,‐,O
40,ministration,O
40,with,O
40,other,O
40,agents,O
40,that,O
40,can,O
40,prolong,O
40,the,O
40,QT,O
40,interval,O
40,may,O
40,result,O
40,in,O
40,additive,O
40,effects,O
40,and,O
40,increased,O
40,risk,O
40,of,O
40,ventricular,O
40,arrhythmias,O
40,including,O
40,torsade,O
40,de,O
40,pointes,O
40,and,O
40,sudden,O
40,death,O
40,.,O
40,Ac,O
40,‐,O
40,cording,O
40,to,O
40,the,O
40,manufacturer,TITLE
40,.,O
40,prolongation,O
40,of,O
40,D,O
40,Bishara,PERSON
40,.,O
40,C,O
40,Kalafatis,PERSON
40,et,O
40,al,O
40,.,O
40,the,O
40,QT,O
40,interval,O
40,has,O
40,been,O
40,reported,O
40,very,O
40,rarely,O
40,in,O
40,patients,O
40,with,O
40,impaired,O
40,renal,O
40,function,O
40,whose,O
40,dose,O
40,/,O
40,dosing,O
40,in,O
40,‐,O
40,terval,O
40,of,O
40,FAM,O
40,may,O
40,not,O
40,have,O
40,been,O
40,adjusted,O
40,appropriately,O
40,.,O
40,In,O
40,gener,O
40,‐,O
40,al,O
40,.,O
40,the,O
40,risk,O
40,of,O
40,an,O
40,individual,O
40,agent,O
40,.,O
40,or,O
40,a,O
40,combination,O
40,of,O
40,these,O
40,agents,O
40,.,O
40,causing,O
40,ventricular,O
40,arrhythmia,O
40,in,O
40,association,O
40,with,O
40,be,O
40,in,O
40,‐,O
40,creased,O
40,by,O
40,certain,O
40,underlying,O
40,risk,O
40,factors,O
40,such,O
40,as,O
40,congenital,O
40,long,O
40,QT,O
40,syndrome,O
40,.,O
40,cardiac,O
40,disease,CAUSE_OF_DEATH
40,and,O
40,electrolyte,O
40,disturbances,O
40,(,O
40,e.g.,O
40,hypokalemia,O
40,.,O
40,hypomagnesemia,O
40,),O
40,.,O
40,In,O
40,addition,O
40,.,O
40,the,O
40,extent,O
40,of,O
40,drug,O
40,‐,O
40,induced,O
40,QT,O
40,prolongation,O
40,is,O
40,dependent,O
40,on,O
40,the,O
40,particular,O
40,drug,O
40,(,O
40,s,O
40,),O
40,involved,O
40,and,O
40,dosage,O
40,(,O
40,s,O
40,),O
40,of,O
40,the,O
40,drug,O
40,(,O
40,s,O
40,),O
40,.,O
40,Acetyl,O
40,‐,O
40,cholinesterase,O
40,inhibitors,O
40,may,O
40,have,O
40,vagotonic,O
40,effects,O
40,on,O
40,the,O
40,sinoatrial,O
40,and,O
40,atrioventricular,O
40,nodes,O
40,.,O
40,which,O
40,occasionally,O
40,mani,O
40,‐,O
40,fest,O
40,as,O
40,bradycardia,O
40,or,O
40,heart,O
40,block,O
40,(,O
40,<,O
40,2,PERCENT
40,%,PERCENT
40,),O
40,.,O
40,Because,O
40,bradycardia,O
40,is,O
40,a,O
40,risk,O
40,factor,O
40,for,O
40,torsade,O
40,de,O
40,pointes,O
40,.,O
40,a,O
40,theoretical,O
40,risk,O
40,exists,O
40,when,O
40,combined,O
40,with,O
40,agents,O
40,drug,O
40,interactions,O
40,with,O
40,psychotropic,O
40,agents,O
40,.,O
40,Favipiravir,O
40,(,O
40,FAVI,O
40,),O
40,is,O
40,an,O
40,anti,O
40,‐,O
40,viral,O
40,drug,O
40,[,O
40,used,O
40,in,O
40,severe,O
40,acute,O
40,respiratory,O
40,syndrome,O
40,(,O
40,SARS,O
40,),O
40,and,O
40,Middle,LOCATION
40,East,LOCATION
40,respiratory,O
40,syndrome,O
40,(,O
40,MERS,O
40,),O
40,],O
40,that,O
40,has,O
40,secured,O
40,approval,O
40,from,O
40,the,O
40,National,O
40,Med,O
40,‐,O
40,ical,O
40,Products,O
40,Administration,O
40,of,O
40,China,COUNTRY
40,to,O
40,treat,O
40,coronavirus,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,An,O
40,open,O
40,‐,O
40,label,O
40,study,O
40,compared,O
40,FAVI,O
40,(,O
40,35,NUMBER
40,patients,O
40,),O
40,with,O
40,LPV,O
40,/,O
40,r,O
40,(,O
40,45,NUMBER
40,patients,O
40,),O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,COVID,O
40,‐,O
40,19.31,NUMBER
40,FAVI,O
40,was,O
40,noted,O
40,to,O
40,have,O
40,shown,O
40,significantly,O
40,better,O
40,treatment,O
40,effects,O
40,on,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,in,O
40,terms,O
40,of,O
40,disease,CAUSE_OF_DEATH
40,progression,O
40,and,O
40,viral,O
40,clearance,O
40,.,O
40,Available,O
40,dosage,O
40,information,O
40,.,O
40,Patients,O
40,in,O
40,the,O
40,study,O
40,received,O
40,oral,O
40,FAVI,O
40,(,O
40,day,DURATION
40,1,NUMBER
40,:,O
40,1600,NUMBER
40,mg,O
40,twice,O
40,daily,SET
40,;,O
40,day,DURATION
40,214,NUMBER
40,600,NUMBER
40,mg,O
40,twice,O
40,daily,SET
40,),O
40,plus,O
40,IFN,O
40,‐,O
40,by,O
40,aerosol,O
40,inhalation,O
40,(,O
40,5,NUMBER
40,million,NUMBER
40,U,O
40,twice,O
40,daily,SET
40,),O
40,or,O
40,LPV,O
40,/,O
40,r,O
40,(,O
40,days,DURATION
40,114,NUMBER
40,:,O
40,400,NUMBER
40,mg,O
40,/,O
40,100,NUMBER
40,mg,O
40,twice,O
40,daily,SET
40,plus,O
40,IFN,O
40,‐,O
40,by,O
40,aerosol,O
40,inhalation,O
40,(,O
40,5,NUMBER
40,million,NUMBER
40,U,O
40,twice,O
40,daily,SET
40,),O
40,.31,NUMBER
40,Adverse,O
40,effects,O
40,.,O
40,In,O
40,the,O
40,small,O
40,study,O
40,described,O
40,previously,DATE
40,.,O
40,two,NUMBER
40,patients,O
40,reported,O
40,diar,O
40,‐,O
40,rhoea,O
40,.,O
40,one,NUMBER
40,had,O
40,liver,O
40,injury,O
40,and,O
40,one,NUMBER
40,had,O
40,poor,CAUSE_OF_DEATH
40,diet,CAUSE_OF_DEATH
40,.31,NUMBER
40,Drug,O
40,inter,O
40,‐,O
40,actions,O
40,.,O
40,FAVI,ORGANIZATION
40,is,O
40,a,O
40,weak,O
40,inhibitor,O
40,of,O
40,CYPs,O
40,1A2,O
40,.,O
40,2C9,O
40,.,O
40,2C19,O
40,.,O
40,2D6,O
40,.,O
40,2E1,O
40,and,O
40,3A4,O
40,and,O
40,showed,O
40,little,O
40,or,O
40,no,O
40,induction,O
40,of,O
40,CYPs,O
40,1A2,O
40,.,O
40,2C9,O
40,.,O
40,2C19,O
40,and,O
40,3A4,O
40,in,O
40,human,O
40,hepatocytes,O
40,.,O
40,FAVI,O
40,inhibits,O
40,CYP2C8,O
40,and,O
40,cau,O
40,‐,O
40,tion,O
40,is,O
40,required,O
40,in,O
40,combination,O
40,with,O
40,drugs,CRIMINAL_CHARGE
40,metabolised,O
40,via,O
40,this,O
40,route,O
40,.,O
40,It,O
40,is,O
40,also,O
40,a,O
40,moderate,O
40,inhibitor,O
40,of,O
40,OAT1,O
40,and,O
40,OAT3,O
40,.,O
40,A,O
40,study,O
40,showed,O
40,increased,O
40,areas,O
40,under,O
40,the,O
40,plasma,O
40,concentration,O
40,‐,O
40,time,O
40,curves,O
40,(,O
40,AUC,O
40,),O
40,of,O
40,paracetamol,O
40,.,O
40,and,O
40,as,O
40,a,O
40,result,O
40,maximum,O
40,dose,O
40,should,O
40,be,O
40,3000,NUMBER
40,mg,O
40,/,O
40,day,DURATION
40,.,O
40,The,O
40,QT,O
40,interval,O
40,prolongation,O
40,risk,O
40,is,O
40,considered,O
40,to,O
40,be,O
40,low,O
40,with,O
40,FAVI,O
40,.9,NUMBER
40,Based,O
40,on,O
40,the,O
40,information,O
40,previously,DATE
40,mentioned,O
40,.,O
40,some,O
40,psychotropic,O
40,levels,O
40,are,O
40,expected,O
40,be,O
40,increased,O
40,due,O
40,to,O
40,weak,O
40,CYP,O
40,inhibition,O
40,by,O
40,FAVI,O
40,.,O
40,but,O
40,since,O
40,there,O
40,are,O
40,no,O
40,reports,O
40,of,O
40,this,O
40,.,O
40,they,O
40,are,O
40,not,O
40,therefore,O
40,be,O
40,required,O
40,but,O
40,it,O
40,is,O
40,important,O
40,to,O
40,be,O
40,aware,O
40,of,O
40,a,O
40,potential,O
40,interaction,O
40,.,O
40,Caution,O
40,is,O
40,recommended,O
40,when,O
40,FAVI,O
40,is,O
40,co,O
40,‐,O
40,administered,O
40,with,O
40,zopiclone,O
40,as,O
40,it,O
40,is,O
40,a,O
40,CYP2C8,O
40,sub,O
40,‐,O
40,strate,O
40,.,O
40,LPV,O
40,/,O
40,r,O
40,is,O
40,an,O
40,oral,O
40,antiretroviral,O
40,protease,O
40,inhibitor,O
40,cur,O
40,‐,O
40,rently,O
40,approved,O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,HIV,CAUSE_OF_DEATH
40,infection,CAUSE_OF_DEATH
40,.,O
40,LPV,O
40,/,O
40,r,O
40,has,O
40,been,O
40,used,O
40,in,O
40,clinical,O
40,trials,O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,Re,O
40,‐,O
40,sults,O
40,from,O
40,one,NUMBER
40,small,O
40,case,O
40,series,O
40,found,O
40,that,O
40,evidence,O
40,of,O
40,clinical,O
40,benefit,O
40,with,O
40,LPV,O
40,/,O
40,r,O
40,was,O
40,equivocal,O
40,.32,NUMBER
40,A,O
40,randomised,O
40,controlled,O
40,trial,O
40,of,O
40,199,NUMBER
40,patients,O
40,in,O
40,China,COUNTRY
40,found,O
40,that,O
40,treatment,O
40,with,O
40,LPV,O
40,/,O
40,r,O
40,was,O
40,not,O
40,beneficial,O
40,compared,O
40,with,O
40,standard,O
40,care,O
40,alone,O
40,(,O
40,primary,O
40,outcome,O
40,was,O
40,time,O
40,to,O
40,improvement,O
40,),O
40,in,O
40,hospitalised,O
40,patients,O
40,with,O
40,severe,O
40,COVID,O
40,‐,O
40,19.12,NUMBER
40,Dosing,O
40,information,O
40,.,O
40,LPV,O
40,/,O
40,r,O
40,(,O
40,400,NUMBER
40,mg,O
40,and,O
40,100,NUMBER
40,mg,O
40,),O
40,orally,O
40,twice,O
40,daily,SET
40,.,O
40,plus,O
40,standard,O
40,care,O
40,for,O
40,14,DURATION
40,days,DURATION
40,was,O
40,used,O
40,in,O
40,the,O
40,clin,O
40,‐,O
40,ical,O
40,trial,O
40,.33,NUMBER
40,Adverse,O
40,effects,O
40,.,O
40,In,O
40,the,O
40,trial,O
40,.,O
40,gastrointestinal,O
40,ad,O
40,‐,O
40,verse,O
40,events,O
40,including,O
40,nausea,O
40,.,O
40,vomiting,O
40,and,O
40,diarrhoea,CAUSE_OF_DEATH
40,were,O
40,more,O
40,common,O
40,in,O
40,the,O
40,LPV,O
40,/,O
40,r,O
40,group,O
40,than,O
40,in,O
40,the,O
40,standard,O
40,‐,O
40,care,O
40,group,O
40,.,O
40,but,O
40,serious,O
40,adverse,O
40,events,O
40,were,O
40,more,O
40,common,O
40,in,O
40,the,O
40,standard,O
40,‐,O
40,care,O
40,group,O
40,.,O
40,Drug,O
40,interactions,O
40,.,O
40,Lopinavir,O
40,is,O
40,metabolised,O
40,extensively,O
40,by,O
40,the,O
40,hepatic,O
40,cytochrome,O
40,P450,O
40,system,O
40,.,O
40,almost,O
40,exclusively,O
40,by,O
40,CYP3A,O
40,.,O
40,Ritonavir,MISC
40,is,O
40,also,O
40,noted,O
40,to,O
40,be,O
40,extensively,O
40,metabolised,O
40,by,O
40,the,O
40,CYP3A,O
40,isozyme,O
40,family,O
40,and,O
40,to,O
40,a,O
40,lesser,O
40,extent,O
40,by,O
40,the,O
40,CYP2D6,O
40,isoform,O
40,.,O
40,Ritonavir,O
40,is,O
40,a,O
40,potent,O
40,CYP3A,O
40,and,O
40,CYP2D6,O
40,inhibitor,O
40,.,O
40,and,O
40,is,O
40,given,O
40,with,O
40,lopinavir,O
40,to,O
40,increase,O
40,plasma,O
40,levels,O
40,of,O
40,lopinavir,O
40,.,O
40,Ri,PERSON
40,‐,PERSON
40,tonavir,O
40,may,O
40,induce,O
40,glucuronidation,O
40,and,O
40,oxidation,O
40,by,O
40,CYP1A2,O
40,.,O
40,CYP2C8,O
40,.,O
40,CYP2C9,O
40,and,O
40,CYP2C19,O
40,.,O
40,thereby,O
40,increasing,O
40,the,O
40,biotransforma,O
40,‐,O
40,tion,O
40,of,O
40,some,O
40,drugs,CRIMINAL_CHARGE
40,metabolised,O
40,by,O
40,these,O
40,pathways,O
40,.,O
40,This,DATE
40,may,DATE
40,result,O
40,in,O
40,decreased,O
40,systemic,O
40,exposure,O
40,of,O
40,these,O
40,agents,O
40,.34,NUMBER
40,Therapeutic,O
40,Ad,O
40,‐,O
40,vances,O
40,in,O
40,Psychopharmacology,O
40,10,NUMBER
40,As,O
40,carbamazepine,O
40,is,O
40,a,O
40,potent,O
40,in,O
40,‐,O
40,ducer,O
40,and,O
40,a,O
40,substrate,O
40,of,O
40,CYP3A4,O
40,.,O
40,co,O
40,‐,O
40,administration,O
40,can,O
40,lead,O
40,to,O
40,both,O
40,reduced,O
40,LPV,O
40,/,O
40,r,O
40,levels,O
40,and,O
40,increased,O
40,carbamazepine,O
40,levels,O
40,.,O
40,Many,O
40,psychotropic,O
40,drugs,CRIMINAL_CHARGE
40,are,O
40,metabolised,O
40,by,O
40,CYP3A4,O
40,.,O
40,and,O
40,so,O
40,the,O
40,ma,O
40,‐,O
40,jority,O
40,will,O
40,experience,O
40,reduced,O
40,metabolism,O
40,and,O
40,increased,O
40,serum,O
40,levels,O
40,when,O
40,administered,O
40,with,O
40,LPV,O
40,/,O
40,r,O
40,(,O
40,see,O
40,highest,O
40,with,O
40,lurasidone,O
40,.,O
40,quetiapine,O
40,and,O
40,ziprasidone,O
40,.,O
40,and,O
40,these,O
40,combinations,O
40,should,O
40,be,O
40,avoided,O
40,.,O
40,In,O
40,contrast,O
40,.,O
40,the,O
40,following,O
40,psychotropics,O
40,are,O
40,expected,O
40,to,O
40,have,O
40,reduced,O
40,serum,O
40,levels,O
40,when,O
40,administered,O
40,with,O
40,LPV,O
40,/,O
40,r,O
40,:,O
40,olan,O
40,‐,O
40,zapine,O
40,.,O
40,agomelatine,O
40,.,O
40,bupropion,O
40,.,O
40,sertraline,O
40,.,O
40,lamotrigine,O
40,.,O
40,val,O
40,‐,O
40,proate,O
40,and,O
40,methadone,CAUSE_OF_DEATH
40,.,O
40,Of,O
40,the,O
40,psychotropics,O
40,evaluated,O
40,.,O
40,the,O
40,levels,O
40,of,O
40,the,O
40,following,O
40,drugs,CRIMINAL_CHARGE
40,are,O
40,not,O
40,expected,O
40,to,O
40,be,O
40,affected,O
40,:,O
40,amisul,O
40,‐,O
40,pride,O
40,.,O
40,sulpiride,O
40,.,O
40,phenelzine,O
40,.,O
40,lorazepam,O
40,.,O
40,oxazepam,O
40,.,O
40,lithium,O
40,.,O
40,ri,O
40,‐,O
40,vastigmine,O
40,.,O
40,memantine,O
40,and,O
40,pregabalin,LOCATION
40,.,O
40,For,O
40,duloxetine,O
40,and,O
40,paroxe,O
40,‐,O
40,tine,O
40,.,O
40,there,O
40,are,O
40,reports,O
40,of,O
40,both,O
40,increase,O
40,and,O
40,decrease,O
40,in,O
40,levels,O
40,when,O
40,given,O
40,with,O
40,LPV,O
40,/,O
40,r.,O
40,LPV,O
40,/,O
40,r,O
40,has,O
40,been,O
40,shown,O
40,to,O
40,cause,O
40,modest,O
40,asymptomatic,O
40,prolongation,O
40,of,O
40,the,O
40,PR,STATE_OR_PROVINCE
40,interval,O
40,in,O
40,some,O
40,healthy,O
40,adult,O
40,subjects,O
40,.,O
40,Rare,O
40,reports,O
40,of,O
40,2nd,ORDINAL
40,and,ORDINAL
40,3rd,ORDINAL
40,degree,O
40,atrioventricu,O
40,‐,O
40,lar,O
40,block,O
40,in,O
40,patients,O
40,with,O
40,underlying,O
40,structural,O
40,heart,CAUSE_OF_DEATH
40,disease,CAUSE_OF_DEATH
40,and,O
40,pre,O
40,‐,O
40,existing,O
40,conduction,O
40,system,O
40,abnormalities,O
40,in,O
40,patients,O
40,re,O
40,‐,O
40,ceiving,O
40,drugs,CRIMINAL_CHARGE
40,known,O
40,to,O
40,prolong,O
40,the,O
40,PR,STATE_OR_PROVINCE
40,interval,O
40,(,O
40,e.g.,O
40,verapamil,O
40,or,O
40,ATV,O
40,),O
40,have,O
40,been,O
40,reported,O
40,.,O
40,LPV,O
40,/,O
40,r,O
40,should,O
40,be,O
40,used,O
40,with,O
40,caution,O
40,in,O
40,such,O
40,patients,O
40,.9,NUMBER
40,As,O
40,many,O
40,antipsychotic,O
40,drugs,CRIMINAL_CHARGE
40,.,O
40,some,O
40,antidepressants,O
40,and,O
40,lithium,O
40,can,O
40,also,O
40,cause,O
40,cardiac,O
40,adverse,O
40,effects,O
40,.,O
40,co,O
40,‐,O
40,adminis,O
40,‐,O
40,tration,O
40,with,O
40,LPV,O
40,/,O
40,r,O
40,can,O
40,cause,O
40,pharmacodynamic,O
40,drug,O
40,interactions,O
40,leading,O
40,to,O
40,increased,O
40,cardiac,O
40,risks,O
40,.,O
40,In,O
40,addition,O
40,.,O
40,LPV,O
40,/,O
40,r,O
40,is,O
40,report,O
40,‐,O
40,ed,O
40,to,O
40,commonly,O
40,cause,O
40,respiratory,CAUSE_OF_DEATH
40,infections,CAUSE_OF_DEATH
40,and,O
40,neutropenia,O
40,.,O
40,both,O
40,of,O
40,these,O
40,will,O
40,be,O
40,added,O
40,risk,O
40,factors,O
40,in,O
40,patients,O
40,with,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,especially,O
40,in,O
40,those,O
40,on,O
40,psychotropics,O
40,that,O
40,can,O
40,also,O
40,cause,O
40,neu,O
40,‐,O
40,tropenia,O
40,.,O
40,for,O
40,example,O
40,clozapine,O
40,and,O
40,carbamazepine,O
40,.,O
40,Nitazoxanide,PERSON
40,(,O
40,NITAZ,O
40,),O
40,an,O
40,antiprotozoal,O
40,that,O
40,is,O
40,currently,DATE
40,FDA,ORGANIZATION
40,approved,O
40,for,O
40,treating,O
40,cryptosporidium,O
40,and,O
40,giardia,O
40,shown,O
40,to,O
40,have,O
40,broad,O
40,antivi,O
40,‐,O
40,ral,O
40,activity,O
40,and,O
40,has,O
40,been,O
40,approved,O
40,in,O
40,some,O
40,countries,O
40,for,O
40,treating,O
40,noro,O
40,and,O
40,rota,O
40,viruses,O
40,.35,NUMBER
40,Proposed,O
40,dosing,O
40,regimen36,O
40,1,NUMBER
40,),O
40,HCLQ,O
40,400,NUMBER
40,mg,O
40,twice,O
40,a,DURATION
40,day,DURATION
40,for,O
40,23,DURATION
40,days,DURATION
40,(,O
40,loading,O
40,),O
40,then,O
40,200,NUMBER
40,mg,O
40,twice,O
40,a,DURATION
40,day,DURATION
40,for,O
40,2,NUMBER
40,),O
40,NITAZ,O
40,(,O
40,600,NUMBER
40,mg,O
40,‐,O
40,SR,O
40,tabs,O
40,),O
40,twice,O
40,a,DURATION
40,day,DURATION
40,;,O
40,if,O
40,unavailable,O
40,.,O
40,using,O
40,the,O
40,immediate,O
40,release,O
40,formulation,O
40,500,NUMBER
40,mg,O
40,three,NUMBER
40,times,O
40,a,DURATION
40,day,DURATION
40,for,O
40,7,DURATION
40,days,DURATION
40,(,O
40,absorption,O
40,better,O
40,with,O
40,food,O
40,),O
40,should,O
40,achieve,O
40,adequate,O
40,trough,O
40,lev,O
40,‐,O
40,els,O
40,that,O
40,easily,O
40,exceeds,O
40,the,O
40,EC50,O
40,of,O
40,SARS,O
40,‐,O
40,CoV2,O
40,.,O
40,The,O
40,duration,O
40,of,O
40,treatment,O
40,can,O
40,likely,O
40,be,O
40,adjusted,O
40,based,O
40,on,O
40,clinical,O
40,response,O
40,.,O
40,Ad,O
40,‐,O
40,verse,O
40,effects,O
40,.,O
40,NITAZ,ORGANIZATION
40,has,O
40,an,O
40,excellent,O
40,safety,O
40,record,O
40,.,O
40,though,O
40,some,O
40,gastrointestinal,O
40,adverse,O
40,effects,O
40,are,O
40,reported,O
40,.,O
40,Drug,O
40,interac,O
40,‐,O
40,tions,O
40,.,O
40,Although,O
40,no,O
40,drugdrug,O
40,interaction,O
40,studies,O
40,have,O
40,been,O
40,con,O
40,‐,O
40,ducted,O
40,in,O
40,vivo,O
40,.,O
40,it,O
40,is,O
40,expected,O
40,that,O
40,no,O
40,significant,O
40,interactions,O
40,would,O
40,occur,O
40,when,O
40,NITAZ,ORGANIZATION
40,is,O
40,co,O
40,‐,O
40,administered,O
40,with,O
40,drugs,CRIMINAL_CHARGE
40,that,O
40,either,O
40,are,O
40,metabolised,O
40,by,O
40,or,O
40,inhibit,O
40,CYP,O
40,450,NUMBER
40,enzymes,O
40,.,O
40,Caution,O
40,should,O
40,.,O
40,however,O
40,.,O
40,be,O
40,used,O
40,when,O
40,administering,O
40,NITAZ,O
40,concurrently,O
40,with,O
40,other,O
40,highly,O
40,plasma,O
40,protein,O
40,‐,O
40,bound,O
40,drugs,CRIMINAL_CHARGE
40,with,O
40,narrow,O
40,therapeutic,O
40,index,O
40,.,O
40,as,O
40,competition,O
40,for,O
40,binding,O
40,sites,O
40,may,O
40,occur,O
40,.,O
40,NITAZ,O
40,can,O
40,therefore,O
40,increase,O
40,adverse,O
40,effects,O
40,of,O
40,benzodiazepines,O
40,is,O
40,recommended,O
40,.,O
40,espe,O
40,‐,O
40,cially,O
40,with,O
40,regards,O
40,to,O
40,respiratory,O
40,depression,O
40,as,O
40,this,O
40,can,O
40,be,O
40,an,O
40,issue,O
40,in,O
40,patients,O
40,with,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,who,O
40,already,O
40,may,O
40,be,O
40,experiencing,O
40,respiratory,O
40,distress,O
40,.,O
40,When,O
40,administered,O
40,with,O
40,food,O
40,.,O
40,the,O
40,AUC,O
40,of,O
40,NITAZ,ORGANIZATION
40,in,O
40,oral,O
40,form,O
40,increased,O
40,by,O
40,around,O
40,50,PERCENT
40,%,PERCENT
40,and,O
40,subsequently,O
40,is,O
40,recommended,O
40,to,O
40,be,O
40,taken,O
40,with,O
40,food,O
40,.,O
40,No,O
40,clinically,O
40,significant,O
40,ef,O
40,‐,O
40,fect,O
40,on,O
40,QTc,O
40,prolongation,O
40,has,O
40,been,O
40,observed,O
40,.9,NUMBER
40,Remdesivir,O
40,‐,O
40,GS,O
40,‐,O
40,5734,DATE
40,(,O
40,RDV,O
40,),O
40,is,O
40,a,O
40,novel,O
40,.,O
40,investigational,O
40,.,O
40,intravenous,O
40,nucleoside,O
40,ana,O
40,‐,O
40,logue,O
40,(,O
40,originally,O
40,used,O
40,to,O
40,treat,O
40,Ebola,O
40,),O
40,with,O
40,broad,O
40,antiviral,O
40,ac,O
40,‐,O
40,tivity,O
40,that,O
40,shows,O
40,in,O
40,vitro,O
40,activity,O
40,against,O
40,severe,O
40,acute,O
40,respira,O
40,‐,O
40,tory,O
40,syndrome,O
40,coronavirus,O
40,2,NUMBER
40,(,O
40,SARS,O
40,‐,O
40,CoV,O
40,‐,O
40,2,NUMBER
40,),O
40,.38,NUMBER
40,Several,O
40,clinical,O
40,tri,O
40,‐,O
40,als,O
40,with,O
40,RDV,O
40,are,O
40,underway,O
40,in,O
40,patients,O
40,with,O
40,mild,O
40,‐,O
40,to,O
40,‐,O
40,severe,O
40,COVID,O
40,‐,O
40,19.39,NUMBER
40,It,O
40,has,O
40,been,O
40,used,O
40,on,O
40,a,O
40,compassionate,O
40,‐,O
40,use,O
40,basis,O
40,in,O
40,ar,O
40,‐,O
40,eas,O
40,where,O
40,clinical,O
40,trials,O
40,are,O
40,not,O
40,available,O
40,;,O
40,however,O
40,.,O
40,the,O
40,manu,O
40,‐,O
40,facturer,O
40,has,O
40,paused,O
40,access,O
40,to,O
40,the,O
40,drug,O
40,via,O
40,this,O
40,route,O
40,due,O
40,to,O
40,overwhelming,O
40,demand,O
40,while,O
40,they,O
40,transition,O
40,to,O
40,an,O
40,expanded,O
40,access,O
40,programme,O
40,.,O
40,Exceptions,O
40,will,O
40,be,O
40,made,O
40,for,O
40,patients,O
40,with,O
40,severe,O
40,ill,O
40,‐,O
40,ness,O
40,.,O
40,and,O
40,pregnant,O
40,women,O
40,and,O
40,children,O
40,with,O
40,confirmed,O
40,infection,CAUSE_OF_DEATH
40,.40,NUMBER
40,D,O
40,Bishara,PERSON
40,.,O
40,C,O
40,Kalafatis,PERSON
40,et,O
40,al,O
40,.,O
40,In,O
40,a,O
40,recent,O
40,cohort,O
40,of,O
40,61,NUMBER
40,hospi,O
40,‐,O
40,talised,O
40,patients,O
40,who,O
40,received,O
40,RDV,O
40,on,O
40,a,O
40,compassionate,O
40,basis,O
40,.,O
40,clin,O
40,‐,O
40,ical,O
40,improvement,O
40,was,O
40,observed,O
40,in,O
40,36,NUMBER
40,of,O
40,53,NUMBER
40,patients,O
40,(,O
40,68,PERCENT
40,%,PERCENT
40,),O
40,.,O
40,A,O
40,total,O
40,of,O
40,25,NUMBER
40,patients,O
40,(,O
40,47,PERCENT
40,%,PERCENT
40,),O
40,were,O
40,discharged,O
40,.,O
40,and,O
40,7,NUMBER
40,patients,O
40,(,O
40,13,PERCENT
40,%,PERCENT
40,),O
40,died,O
40,.41,NUMBER
40,Dosing,O
40,information,O
40,.,O
40,Limited,O
40,data,O
40,available,O
40,;,O
40,dosing,O
40,used,O
40,in,O
40,clinical,O
40,trials,O
40,:,O
40,200,NUMBER
40,mg,O
40,as,O
40,a,O
40,single,O
40,dose,O
40,on,O
40,day,DURATION
40,1,NUMBER
40,.,O
40,followed,O
40,by,O
40,100,NUMBER
40,mg,O
40,once,DATE
40,daily,SET
40,until,O
40,day,DURATION
40,5,NUMBER
40,or,O
40,10,NUMBER
40,in,O
40,addition,O
40,to,O
40,standard,O
40,care,O
40,.42.43,NUMBER
40,Adverse,O
40,effects,O
40,.,O
40,The,O
40,information,O
40,on,O
40,adverse,O
40,effects,O
40,is,O
40,also,O
40,limited,O
40,however,O
40,it,O
40,has,O
40,been,O
40,reported,O
40,to,O
40,cause,O
40,nausea,O
40,and,O
40,in,O
40,‐,O
40,crease,O
40,liver,O
40,enzymes,O
40,(,O
40,which,O
40,may,O
40,or,O
40,may,O
40,not,O
40,indicate,O
40,liver,O
40,dam,O
40,‐,O
40,age,O
40,),O
40,.,O
40,It,O
40,does,O
40,not,O
40,prolong,O
40,QTc,O
40,interval,O
40,.44,NUMBER
40,Drug,O
40,interactions,O
40,.,O
40,Based,O
40,on,O
40,rapid,O
40,distribution,O
40,.,O
40,metabolism,O
40,and,O
40,clearance,O
40,.,O
40,the,O
40,like,O
40,‐,O
40,lihood,O
40,of,O
40,clinically,O
40,significant,O
40,interactions,O
40,is,O
40,low,O
40,.,O
40,RDV,O
40,is,O
40,a,O
40,substrate,O
40,of,O
40,CYP,O
40,2C8,O
40,.,O
40,CYP,O
40,2D6,O
40,.,O
40,CYP,O
40,3A4,O
40,and,O
40,transporters,O
40,OATP1B1,O
40,and,O
40,P,O
40,‐,O
40,gp,O
40,in,O
40,vitro,O
40,.,O
40,but,O
40,coadministration,O
40,with,O
40,inhibitors,O
40,of,O
40,these,O
40,CYP,O
40,isoforms,O
40,and,O
40,transporters,O
40,is,O
40,unlikely,O
40,to,O
40,increase,O
40,its,O
40,lev,O
40,‐,O
40,els,O
40,.9,NUMBER
40,RDV,O
40,can,O
40,be,O
40,impacted,O
40,by,O
40,strong,O
40,inducers,O
40,(,O
40,e.g.,O
40,carbamazepine,O
40,),O
40,thus,O
40,co,O
40,‐,O
40,administration,O
40,is,O
40,not,O
40,recommended,O
40,.,O
40,RDV,O
40,is,O
40,an,O
40,inducer,O
40,of,O
40,CYP,O
40,1A2,O
40,and,O
40,CYP,O
40,2B6,O
40,in,O
40,vitro,O
40,but,O
40,.,O
40,considering,O
40,the,O
40,exposure,O
40,.,O
40,it,O
40,is,O
40,unlikely,O
40,to,O
40,translate,O
40,into,O
40,clinically,O
40,significant,O
40,interaction,O
40,with,O
40,substrates,O
40,of,O
40,these,O
40,enzymes,O
40,.9,NUMBER
40,However,O
40,.,O
40,caution,O
40,should,O
40,be,O
40,used,O
40,when,O
40,co,O
40,‐,O
40,administered,O
40,with,O
40,clozapine,O
40,(,O
40,CYP1A2,O
40,substrate,O
40,),O
40,and,O
40,methadone,CAUSE_OF_DEATH
40,(,O
40,CYP2B6,O
40,substrate,O
40,),O
40,as,O
40,.,O
40,theoretically,O
40,.,O
40,for,O
40,effects,O
40,on,O
40,other,O
40,psychotropics,O
40,as,O
40,well,O
40,),O
40,.,O
40,Since,O
40,there,O
40,are,O
40,limited,O
40,data,O
40,on,O
40,the,O
40,tolerability,O
40,and,O
40,adverse,O
40,effect,O
40,profile,O
40,of,O
40,RDV,O
40,.,O
40,it,O
40,is,O
40,diffi,O
40,‐,O
40,cult,RELIGION
40,to,O
40,predict,O
40,whether,O
40,any,O
40,pharmacodynamic,O
40,interactions,O
40,with,O
40,psychotropics,O
40,exist,O
40,.,O
40,Reports,O
40,of,O
40,increased,O
40,liver,O
40,enzymes,O
40,may,O
40,sug,O
40,‐,O
40,gest,O
40,that,O
40,monitoring,O
40,may,O
40,be,O
40,warranted,O
40,in,O
40,some,O
40,patients,O
40,.,O
40,especial,O
40,‐,O
40,ly,O
40,if,O
40,co,O
40,‐,O
40,prescribed,O
40,psychotropics,O
40,that,O
40,can,O
40,also,O
40,increase,O
40,liver,O
40,enzymes,O
40,or,O
40,affect,O
40,liver,O
40,function,O
40,for,O
40,example,O
40,.,O
40,agomelatine,O
40,.,O
40,monoamine,O
40,oxidase,O
40,inhibitors,O
40,.,O
40,carbamazepine,O
40,or,O
40,haloperidol,O
40,.,O
40,Rib,O
40,‐,O
40,avirin,O
40,(,O
40,RBV,O
40,),O
40,is,O
40,an,O
40,antiviral,O
40,used,O
40,to,O
40,treat,O
40,hepatitis,O
40,and,O
40,has,O
40,been,O
40,used,O
40,previously,DATE
40,to,O
40,manage,O
40,SARS,O
40,and,O
40,MERS,O
40,patients,O
40,.,O
40,An,O
40,open,O
40,‐,O
40,label,O
40,.,O
40,randomised,O
40,controlled,O
40,trial,O
40,currently,DATE
40,underway,O
40,in,O
40,China,COUNTRY
40,included,O
40,three,NUMBER
40,regimens,O
40,with,O
40,the,O
40,following,O
40,RBV,O
40,(,O
40,intravenous,O
40,loading,O
40,dose,O
40,of,O
40,2,NUMBER
40,g,O
40,.,O
40,followed,O
40,by,O
40,oral,O
40,doses,O
40,of,O
40,400600,NUMBER
40,mg,O
40,every,O
40,8,NUMBER
40,h,O
40,depending,O
40,on,O
40,the,O
40,patients,O
40,weight,O
40,.,O
40,for,O
40,14,DURATION
40,days,DURATION
40,),O
40,;,O
40,LPV,O
40,/,O
40,r,O
40,(,O
40,oral,O
40,.,O
40,400,NUMBER
40,mg,O
40,/,O
40,100,NUMBER
40,mg,O
40,per,O
40,dose,O
40,.,O
40,twice,O
40,a,DURATION
40,day,DURATION
40,.,O
40,for,O
40,14,DURATION
40,days,DURATION
40,),O
40,;,O
40,IFN,O
40,‐‐,O
40,1b,NUMBER
40,(,O
40,atomizing,O
40,inhala,O
40,‐,O
40,tion,O
40,.,O
40,5,NUMBER
40,million,NUMBER
40,U,O
40,or,O
40,50,NUMBER
40,g,O
40,per,O
40,dose,O
40,.,O
40,twice,O
40,a,DURATION
40,day,DURATION
40,.,O
40,for,O
40,14,DURATION
40,days,DURATION
40,),O
40,.,O
40,And,O
40,comparing,O
40,the,O
40,effectiveness,O
40,of,O
40,:,O
40,RBV,O
40,plus,O
40,IFN,O
40,‐,O
40,1b,NUMBER
40,(,O
40,arm,O
40,A,O
40,),O
40,;,O
40,LPV,O
40,/,O
40,r,O
40,plus,O
40,IFN,O
40,‐,O
40,1b,NUMBER
40,(,O
40,arm,O
40,B,O
40,),O
40,;,O
40,and,O
40,RBV,O
40,plus,O
40,LPV,O
40,/,O
40,r,O
40,plus,O
40,IFN,O
40,‐,O
40,1b,NUMBER
40,(,O
40,arm,O
40,C,O
40,),O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,Adverse,O
40,effects46,O
40,.,O
40,Pancytopenia,O
40,and,O
40,bone,O
40,marrow,O
40,suppression,O
40,have,O
40,been,O
40,reported,O
40,with,O
40,RBV,O
40,.,O
40,No,O
40,ef,O
40,‐,O
40,fect,O
40,on,O
40,QTc,O
40,prolongation,O
40,has,O
40,been,O
40,observed,O
40,.,O
40,There,O
40,are,O
40,several,O
40,serious,O
40,adverse,O
40,reactions,O
40,associated,O
40,with,O
40,the,O
40,combination,O
40,therapy,O
40,of,O
40,RBV,O
40,with,O
40,(,O
40,peg,O
40,),O
40,IFN,O
40,‐,O
40,.,O
40,These,O
40,include,O
40,:,O
40,‐,O
40,Severe,O
40,psychiatric,O
40,and,O
40,central,O
40,nervous,O
40,system,O
40,effects,O
40,(,O
40,such,O
40,as,O
40,depression,O
40,.,O
40,suicidal,O
40,ideation,O
40,.,O
40,attempted,O
40,suicide,CAUSE_OF_DEATH
40,and,O
40,aggressive,O
40,behaviour,O
40,.,O
40,etc.,O
40,),O
40,;,O
40,‐,O
40,Severe,O
40,ocular,O
40,disorders,O
40,;,O
40,‐,O
40,Dental,O
40,and,O
40,periodontal,O
40,disorders,O
40,.,O
40,Drug,O
40,interactions,O
40,.,O
40,RBV,O
40,has,O
40,two,NUMBER
40,pathways,O
40,of,O
40,metabolism,O
40,:,O
40,a,O
40,re,O
40,‐,O
40,versible,O
40,phosphorylation,O
40,pathway,O
40,and,O
40,a,O
40,degradative,O
40,pathway,O
40,.,O
40,Both,O
40,RBV,O
40,and,O
40,metabolites,O
40,are,O
40,excreted,O
40,renally,O
40,.,O
40,Results,O
40,of,O
40,in,O
40,vitro,O
40,studies,O
40,indicated,O
40,no,O
40,CYP,O
40,450,NUMBER
40,enzyme,O
40,‐,O
40,mediated,O
40,metabolism,O
40,of,O
40,RBV,O
40,.,O
40,RBV,O
40,does,O
40,not,O
40,inhibit,O
40,CYP,O
40,450,NUMBER
40,enzymes,O
40,and,O
40,there,O
40,is,O
40,no,O
40,evidence,O
40,from,O
40,toxicity,O
40,studies,O
40,that,O
40,it,O
40,induces,O
40,liver,O
40,enzymes,O
40,.,O
40,therefore,O
40,potential,O
40,for,O
40,P450,O
40,‐,O
40,based,O
40,interactions,O
40,is,O
40,minimal,O
40,.9,NUMBER
40,Information,O
40,on,O
40,drug,O
40,interactions,O
40,with,O
40,RBV,O
40,is,O
40,limited,O
40,.,O
40,The,O
40,Drugbank,O
40,database,O
40,lists,O
40,potential,O
40,pharmacokinetic,O
40,drug,O
40,interactions,O
40,leading,O
40,to,O
40,in,O
40,‐,O
40,creased,O
40,RBV,O
40,levels,O
40,with,O
40,the,O
40,following,O
40,psychotropic,O
40,agents,O
40,:,O
40,cloza,O
40,‐,O
40,pine,O
40,.,O
40,haloperidol,O
40,.,O
40,amitriptyline,O
40,.,O
40,duloxetine,O
40,.,O
40,imipramine,O
40,.,O
40,phenelzine,O
40,.,O
40,venlafaxine,O
40,.,O
40,midazolam,O
40,.,O
40,lamotrigine,O
40,and,O
40,pregabalin,LOCATION
40,.,O
40,It,O
40,is,O
40,not,O
40,clear,O
40,whether,O
40,these,O
40,are,O
40,actual,O
40,reports,O
40,of,O
40,interactions,O
40,or,O
40,theoretical,O
40,considerations,O
40,.,O
40,and,O
40,the,O
40,mechanisms,O
40,are,O
40,not,O
40,clear,O
40,.,O
40,Similarly,O
40,.,O
40,Drugbank,PERSON
40,also,O
40,notes,O
40,that,O
40,RBV,O
40,may,O
40,lead,O
40,to,O
40,increased,O
40,levels,O
40,of,O
40,the,O
40,following,O
40,psychotropic,O
40,agents,O
40,:,O
40,paliperidone,O
40,.,O
40,queti,O
40,‐,O
40,apine,O
40,.,O
40,bupropion,O
40,.,O
40,clomipramine,O
40,.,O
40,desipramine,O
40,.,O
40,vortioxetine,O
40,.,O
40,clon,O
40,‐,O
40,azepam,O
40,.,O
40,diazepam,O
40,.,O
40,oxazepam,O
40,.,O
40,carbamazepine,O
40,and,O
40,lithium,O
40,.,O
40,Therapeu,O
40,‐,O
40,tic,O
40,Advances,O
40,in,O
40,Psychopharmacology,O
40,10,NUMBER
40,Pharmacodynamic,O
40,interac,O
40,‐,O
40,tions,O
40,with,O
40,psychotropics,O
40,include,O
40,infections,CAUSE_OF_DEATH
40,and,O
40,neutropenia,O
40,.,O
40,which,O
40,have,O
40,both,O
40,been,O
40,reported,O
40,with,O
40,RBV,O
40,use,O
40,a,O
40,significant,O
40,risk,O
40,for,O
40,patients,O
40,infected,O
40,with,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,particularly,O
40,if,O
40,also,O
40,taking,O
40,clozapine,O
40,or,O
40,carbamazepine,O
40,.,O
40,also,O
40,known,O
40,to,O
40,cause,O
40,neutropenia,O
40,.,O
40,In,O
40,addition,O
40,.,O
40,combination,O
40,therapy,O
40,of,O
40,RBV,O
40,with,O
40,(,O
40,peg,O
40,),O
40,IFN,O
40,‐,O
40,has,O
40,been,O
40,as,O
40,‐,O
40,sociated,O
40,with,O
40,severe,O
40,psychiatric,O
40,effects,O
40,.,O
40,another,O
40,serious,O
40,concern,O
40,if,O
40,used,O
40,in,O
40,psychiatric,O
40,patients,O
40,.,O
40,Tocilizumab,PERSON
40,(,O
40,TCZ,O
40,),O
40,is,O
40,an,O
40,inter,O
40,‐,O
40,leukin,O
40,(,O
40,IL,STATE_OR_PROVINCE
40,),O
40,‐,O
40,6,NUMBER
40,receptor,O
40,inhibiting,O
40,monoclonal,O
40,antibody,O
40,that,O
40,is,O
40,currently,DATE
40,approved,O
40,for,O
40,rheumatological,O
40,conditions,O
40,such,O
40,as,O
40,rheuma,O
40,‐,O
40,toid,O
40,arthritis,O
40,and,O
40,cytokine,O
40,release,O
40,syndrome,O
40,.,O
40,TCZ,O
40,is,O
40,being,O
40,tri,O
40,‐,O
40,alled,O
40,in,O
40,patients,O
40,with,O
40,severe,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,to,O
40,see,O
40,whether,O
40,it,O
40,is,O
40,ef,O
40,‐,O
40,fective,O
40,in,O
40,reducing,O
40,the,O
40,virus,O
40,‐,O
40,induced,O
40,cytokine,O
40,storm,CAUSE_OF_DEATH
40,.,O
40,thereby,O
40,po,O
40,‐,O
40,tentially,O
40,reducing,O
40,complications,CAUSE_OF_DEATH
40,.47,NUMBER
40,However,O
40,.,O
40,the,O
40,decision,O
40,to,O
40,sup,O
40,‐,O
40,press,O
40,the,O
40,immune,O
40,system,O
40,of,O
40,a,O
40,critically,O
40,unwell,O
40,patient,O
40,with,O
40,COVID19,O
40,is,O
40,a,O
40,difficult,O
40,one,NUMBER
40,;,O
40,the,O
40,beneficial,O
40,anti,O
40,‐,O
40,inflammatory,O
40,ef,O
40,‐,O
40,fects,O
40,of,O
40,TCZ,O
40,(,O
40,or,O
40,any,O
40,other,O
40,anti,O
40,‐,O
40,inflammatory,O
40,drug,O
40,),O
40,must,O
40,be,O
40,weighed,O
40,against,O
40,the,O
40,possibly,O
40,detrimental,O
40,effects,O
40,of,O
40,impairment,O
40,of,O
40,immunity,O
40,.48,NUMBER
40,Patients,O
40,with,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,experience,O
40,an,O
40,elevation,O
40,of,O
40,IL,STATE_OR_PROVINCE
40,‐,O
40,6,NUMBER
40,.,O
40,However,O
40,.,O
40,since,O
40,co,O
40,‐,O
40,medication,O
40,will,O
40,not,O
40,have,O
40,been,O
40,adjusted,O
40,to,O
40,the,O
40,acute,O
40,inflammatory,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,state,O
40,.,O
40,and,O
40,since,O
40,treatment,O
40,with,O
40,TCZ,O
40,would,O
40,have,O
40,been,O
40,initiated,O
40,very,O
40,rapidly,O
40,(,O
40,and,O
40,only,O
40,up,O
40,to,O
40,two,NUMBER
40,doses,O
40,given,O
40,),O
40,.,O
40,no,O
40,prior,O
40,adjustment,O
40,of,O
40,CYP,O
40,substrates,O
40,is,O
40,needed,O
40,.,O
40,But,O
40,the,O
40,effect,O
40,of,O
40,acute,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,infection,CAUSE_OF_DEATH
40,on,O
40,drugs,CRIMINAL_CHARGE
40,with,O
40,narrow,O
40,therapeutic,O
40,index,O
40,is,O
40,unclear,O
40,.9,NUMBER
40,TCZ,O
40,may,O
40,decrease,O
40,blood,O
40,levels,O
40,of,O
40,carbamazepine,O
40,.,O
40,which,O
40,may,O
40,require,O
40,dose,O
40,Caution,O
40,is,O
40,required,O
40,when,O
40,co,O
40,‐,O
40,administering,O
40,with,O
40,myelotoxic,O
40,drugs,CRIMINAL_CHARGE
40,such,O
40,as,O
40,clozapine,O
40,or,O
40,car,O
40,‐,O
40,bamazepine,O
40,due,O
40,to,O
40,the,O
40,potential,O
40,additive,O
40,haematological,O
40,toxicity,O
40,.,O
40,No,O
40,clinically,O
40,significant,O
40,effect,O
40,on,O
40,QT,O
40,prolongation,O
40,was,O
40,observed,O
40,in,O
40,healthy,O
40,subjects,O
40,.9,NUMBER
40,Other,O
40,drugs,CRIMINAL_CHARGE
40,Intravenous,O
40,immunoglobulin,O
40,is,O
40,being,O
40,trialled,O
40,in,O
40,some,O
40,patients,O
40,with,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,;,O
40,however,O
40,.,O
40,there,O
40,are,O
40,no,O
40,data,O
40,to,O
40,support,O
40,this,O
40,.,O
40,Angiotensin,O
40,‐,O
40,II,NUMBER
40,receptor,O
40,antagonists,O
40,such,O
40,as,O
40,losartan,O
40,are,O
40,being,O
40,investigated,O
40,as,O
40,a,O
40,potential,O
40,treatment,O
40,be,O
40,‐,O
40,cause,O
40,it,O
40,is,O
40,thought,O
40,that,O
40,the,O
40,angiotensin,O
40,‐,O
40,converting,O
40,enzyme,O
40,‐,O
40,2,NUMBER
40,(,O
40,ACE2,O
40,),O
40,receptor,O
40,is,O
40,the,O
40,main,O
40,binding,O
40,site,O
40,for,O
40,the,O
40,virus,O
40,.35.36,NUMBER
40,Re,O
40,‐,O
40,ported,O
40,dosage,O
40,has,O
40,been,O
40,:,O
40,The,O
40,initial,O
40,dose,O
40,should,O
40,be,O
40,48,NUMBER
40,mg,O
40,/,O
40,kg,O
40,.,O
40,with,O
40,the,O
40,recommended,O
40,dosage,O
40,being,O
40,400,NUMBER
40,mg,O
40,;,O
40,Dilute,O
40,with,O
40,0.9,PERCENT
40,%,PERCENT
40,saline,O
40,to,O
40,100,NUMBER
40,ml,O
40,and,O
40,infuse,O
40,over,O
40,the,O
40,course,O
40,of,O
40,more,O
40,than,O
40,1,NUMBER
40,h,O
40,;,O
40,Repeat,O
40,once,DATE
40,after,O
40,12,NUMBER
40,h,O
40,(,O
40,same,O
40,dosage,O
40,),O
40,if,O
40,the,O
40,response,O
40,to,O
40,the,O
40,first,ORDINAL
40,dose,O
40,was,O
40,poor,O
40,.,O
40,maximum,O
40,two,NUMBER
40,cumulative,O
40,doses,O
40,;,O
40,Single,O
40,maximum,O
40,dose,O
40,is,O
40,800,NUMBER
40,mg,O
40,.,O
40,Drug,O
40,interactions,O
40,.,O
40,TCZ,O
40,has,O
40,no,O
40,direct,O
40,inhibitory,O
40,or,O
40,inducing,O
40,effects,O
40,on,O
40,CYP,O
40,enzymes,O
40,per,O
40,se,O
40,.,O
40,However,O
40,.,O
40,it,O
40,reverses,O
40,IL,STATE_OR_PROVINCE
40,‐,O
40,6,NUMBER
40,induced,O
40,suppression,O
40,of,O
40,cytochromes,O
40,(,O
40,elevation,O
40,of,O
40,IL,STATE_OR_PROVINCE
40,‐,O
40,6,NUMBER
40,during,O
40,inflammation,O
40,has,O
40,been,O
40,shown,O
40,to,O
40,inhibit,O
40,CYP,O
40,3A4,O
40,.,O
40,CYP2C19,O
40,.,O
40,CUP2C9,O
40,and,O
40,CYP1A2,O
40,ac,O
40,‐,O
40,tivity,O
40,.,O
40,resulting,O
40,in,O
40,higher,O
40,drug,O
40,exposure,O
40,of,O
40,substrate,O
40,drugs,CRIMINAL_CHARGE
40,),O
40,.,O
40,which,O
40,.,O
40,prior,O
40,to,O
40,treatment,O
40,with,O
40,TCZ,O
40,.,O
40,has,O
40,been,O
40,adjusted,O
40,to,O
40,the,O
40,me,O
40,‐,O
40,tabolism,O
40,of,O
40,individuals,O
40,.,O
40,When,O
40,treatment,O
40,with,O
40,TCZ,O
40,is,O
40,started,O
40,.,O
40,cy,O
40,‐,O
40,tochrome,O
40,activity,O
40,normalises,O
40,.,O
40,thus,O
40,leading,O
40,to,O
40,reduced,O
40,exposure,O
40,of,O
40,drugs,CRIMINAL_CHARGE
40,.,O
40,which,O
40,.,O
40,prior,O
40,to,O
40,treatment,O
40,.,O
40,had,O
40,been,O
40,adjusted,O
40,to,O
40,the,O
40,metab,O
40,‐,O
40,olism,O
40,of,O
40,individuals,O
40,with,O
40,the,O
40,rheumatic,O
40,disease,CAUSE_OF_DEATH
40,that,O
40,it,O
40,is,O
40,usual,O
40,‐,O
40,ly,O
40,used,O
40,for,O
40,.9,NUMBER
40,In,O
40,addition,O
40,.,O
40,researchers,O
40,at,O
40,the,O
40,Murdoch,PERSON
40,set,O
40,to,O
40,con,O
40,‐,O
40,duct,O
40,a,O
40,randomised,O
40,.,O
40,multi,O
40,‐,O
40,centre,O
40,clinical,O
40,trial,O
40,to,O
40,test,O
40,the,O
40,use,O
40,of,O
40,tuberculosis,CAUSE_OF_DEATH
40,vaccine,O
40,BCG,O
40,against,O
40,Covid,O
40,‐,O
40,19,NUMBER
40,.,O
40,The,O
40,BRACE,O
40,trial,O
40,is,O
40,in,O
40,‐,O
40,tended,O
40,for,O
40,healthcare,O
40,workers,O
40,.,O
40,It,O
40,is,O
40,based,O
40,on,O
40,previous,O
40,study,O
40,findings,O
40,that,O
40,BCG,ORGANIZATION
40,decreases,O
40,the,O
40,level,O
40,of,O
40,virus,O
40,in,O
40,patients,O
40,in,O
40,‐,O
40,fected,O
40,by,O
40,viruses,O
40,similar,O
40,to,O
40,SARS,O
40,‐,O
40,CoV,O
40,‐,O
40,2.49,NUMBER
40,BCG,O
40,vaccines,O
40,heterolo,O
40,‐,O
40,gous,O
40,beneficial,O
40,effect,O
40,against,O
40,non,O
40,‐,O
40,tuberculosis,CAUSE_OF_DEATH
40,infections,CAUSE_OF_DEATH
40,is,O
40,well,O
40,known,O
40,.,O
40,The,O
40,vaccine,O
40,works,O
40,on,O
40,the,O
40,innate,O
40,immune,O
40,system,O
40,and,O
40,produces,O
40,a,O
40,memory,O
40,like,O
40,response,O
40,termed,O
40,trained,O
40,immunity,O
40,that,O
40,helps,O
40,in,O
40,faster,O
40,recognition,O
40,.,O
40,triggering,O
40,a,O
40,quicker,O
40,inflammatory,O
40,response,O
40,.,O
40,Recent,O
40,studies,O
40,have,O
40,also,O
40,suggested,O
40,that,O
40,it,O
40,has,O
40,the,O
40,po,O
40,‐,O
40,tential,O
40,to,O
40,protect,O
40,against,O
40,experimental,O
40,infection,CAUSE_OF_DEATH
40,with,O
40,yellow,O
40,fever,CAUSE_OF_DEATH
40,vaccine,O
40,strain,O
40,and,O
40,to,O
40,enhance,O
40,immune,O
40,responses,O
40,to,O
40,other,O
40,vaccines,O
40,in,O
40,general,TITLE
40,including,O
40,influenza,CAUSE_OF_DEATH
40,vaccination,O
40,.50,NUMBER
40,We,O
40,urge,O
40,clinicians,O
40,to,O
40,exercise,O
40,significant,O
40,caution,O
40,in,O
40,the,O
40,use,O
40,of,O
40,any,O
40,of,O
40,the,O
40,previously,DATE
40,mentioned,O
40,medications,O
40,even,O
40,on,O
40,a,O
40,compassionate,O
40,‐,O
40,use,O
40,basis,O
40,in,O
40,the,O
40,absence,O
40,of,O
40,adequately,O
40,powered,O
40,and,O
40,/,O
40,or,O
40,D,O
40,Bishara,PERSON
40,.,O
40,C,O
40,Kalafatis,PERSON
40,et,O
40,al,O
40,.,O
40,trials,O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,patients,O
40,.,O
40,An,O
40,even,O
40,higher,O
40,threshold,O
40,of,O
40,vigilance,O
40,should,O
40,be,O
40,maintained,O
40,for,O
40,patients,O
40,with,O
40,pre,O
40,‐,O
40,existing,O
40,conditions,O
40,and,O
40,older,O
40,adults,O
40,due,O
40,to,O
40,added,O
40,toxicity,O
40,and,O
40,many,O
40,psychotropic,O
40,agents,O
40,can,O
40,interact,O
40,with,O
40,agents,O
40,used,O
40,in,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,.,O
40,leading,O
40,to,O
40,serious,O
40,adverse,O
40,effects,O
40,in,O
40,‐,O
40,cluding,O
40,QTc,O
40,prolongation,O
40,thus,O
40,increasing,O
40,the,O
40,risk,O
40,of,O
40,torsades,O
40,de,O
40,pointes,O
40,and,O
40,bone,O
40,marrow,O
40,suppression,O
40,.,O
40,Identifying,O
40,and,O
40,avoiding,O
40,these,O
40,interactions,O
40,can,O
40,be,O
40,vital,O
40,to,O
40,improving,O
40,survival,O
40,in,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,patients,O
40,.,O
40,Conflict,O
40,of,O
40,interest,O
40,statement,O
40,Delia,PERSON
40,Bishara,PERSON
40,David,PERSON
40,Taylor,PERSON
40,1,NUMBER
40,.,O
40,Kalil,PERSON
40,AC,O
40,.,O
40,Treating,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,‐,O
40,off,O
40,‐,O
40,label,O
40,drug,O
40,use,O
40,.,O
40,compas,O
40,‐,O
40,sionate,O
40,use,O
40,.,O
40,and,O
40,randomized,O
40,2,NUMBER
40,.,O
40,Sayburn,O
40,A.,O
40,Covid,O
40,‐,O
40,19,NUMBER
40,:,O
40,trials,O
40,of,O
40,four,NUMBER
40,potential,O
40,treatments,O
40,to,O
40,generate,O
40,robust,O
40,data,O
40,of,O
40,what,O
40,works,O
40,.,O
40,BMJ,O
40,2020,DATE
40,;,O
40,368,NUMBER
40,:,O
40,m1206,O
40,.,O
40,3,NUMBER
40,.,O
40,Recovery,O
40,:,O
40,Randomised,O
40,Evaluation,O
40,of,O
40,COVID19,O
40,Therapy,O
40,.,O
40,This,O
40,nation,O
40,clinical,O
40,trials,O
40,aims,O
40,to,O
40,identify,O
40,treatments,O
40,that,O
40,may,O
40,be,O
40,beneficial,O
40,for,O
40,4,NUMBER
40,.,O
40,Medicines,O
40,Complete,O
40,.,O
40,Stockleys,O
40,interactions,O
40,checker,TITLE
40,.,O
40,stockleys,O
40,‐,O
40,interactions,O
40,‐,O
40,checker,TITLE
40,/,O
40,(,O
40,accessed,O
40,06,DATE
40,May,DATE
40,5,DATE
40,.,O
40,HIV,CAUSE_OF_DEATH
40,Drug,O
40,Interactions,O
40,.,O
40,Interaction,O
40,10,NUMBER
40,.,O
40,Medicines.org.uk,URL
40,.,O
40,Azithromycin,MISC
40,250,NUMBER
40,mg,O
40,capsules,O
40,.,O
40,PROPS,O
40,(,O
40,accessed,O
40,02,DATE
40,April,DATE
40,2020,DATE
40,),O
40,.,O
40,prevention,O
40,of,O
40,coronavirus,O
40,disease,CAUSE_OF_DEATH
40,(,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,),O
40,12,NUMBER
40,.,O
40,Expert,O
40,consensus,O
40,on,O
40,chloroquine,O
40,phosphate,O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,novel,O
40,coronavirus,O
40,pneumonia,CAUSE_OF_DEATH
40,.,O
40,Zhonghua,PERSON
40,Jie,PERSON
40,He,PERSON
40,He,PERSON
40,Hu,PERSON
40,Xi,PERSON
40,Za,PERSON
40,Zhi,PERSON
40,2020,DATE
40,;,O
40,43,NUMBER
40,:,O
40,13,NUMBER
40,.,O
40,Gautret,O
40,P,O
40,.,O
40,Lagier,PERSON
40,JC,PERSON
40,.,O
40,Parola,PERSON
40,P,O
40,.,O
40,et,O
40,al,O
40,.,O
40,Hydroxy,O
40,‐,O
40,chloroquine,O
40,and,O
40,azithromycin,O
40,as,O
40,a,O
40,treatment,O
40,of,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,:,O
40,results,O
40,of,O
40,an,O
40,open,O
40,‐,O
40,label,O
40,non,O
40,‐,O
40,randomized,O
40,clinical,O
40,trial,O
40,.,O
40,Int,PERSON
40,J,PERSON
40,Antimicrob,PERSON
40,14,NUMBER
40,.,O
40,Molina,PERSON
40,JM,PERSON
40,.,O
40,Delaugerre,PERSON
40,C,PERSON
40,.,O
40,Goff,PERSON
40,JL,O
40,.,O
40,et,O
40,al,O
40,.,O
40,No,O
40,evidence,O
40,of,O
40,rapid,O
40,antiviral,O
40,clearance,O
40,or,O
40,clinical,O
40,benefit,O
40,with,O
40,the,O
40,combina,O
40,‐,O
40,tion,O
40,of,O
40,hydroxychloroquine,O
40,and,O
40,azithromycin,O
40,in,O
40,patients,O
40,with,O
40,se,O
40,‐,O
40,vere,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,Infection,CAUSE_OF_DEATH
40,.,O
40,Med,O
40,Mal,O
40,15,NUMBER
40,.,O
40,Chen,PERSON
40,J,PERSON
40,.,O
40,Liu,PERSON
40,D,PERSON
40,.,O
40,Liu,PERSON
40,L,O
40,.,O
40,et,O
40,al,O
40,.,O
40,A,O
40,pilot,TITLE
40,study,O
40,of,O
40,hydroxychloroquine,O
40,in,O
40,treatment,O
40,of,O
40,patients,O
40,with,O
40,common,O
40,coronavirus,O
40,disease,CAUSE_OF_DEATH
40,‐,O
40,19,NUMBER
40,(,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,),O
40,.,O
40,J,O
40,Zhejiang,STATE_OR_PROVINCE
40,Univ,O
40,2020,DATE
40,;,O
40,49,NUMBER
40,:,O
40,215219,NUMBER
40,.,O
40,16,NUMBER
40,.,O
40,Chen,O
40,Z,O
40,.,O
40,Hu,PERSON
40,J,PERSON
40,.,O
40,Zhang,PERSON
40,Z,PERSON
40,.,O
40,et,O
40,al,O
40,.,O
40,Efficacy,O
40,of,O
40,hy,O
40,‐,O
40,droxychloroquine,O
40,in,O
40,patients,O
40,with,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,:,O
40,results,O
40,of,O
40,a,O
40,random,O
40,‐,O
40,ized,O
40,clinical,O
40,trial,O
40,.,O
40,medRxiv,O
40,17,NUMBER
40,.,O
40,Chorin,O
40,E,O
40,.,O
40,Dai,PERSON
40,M,O
40,.,O
40,Shulman,PERSON
40,E,O
40,.,O
40,et,O
40,al,O
40,.,O
40,The,O
40,QT,O
40,interval,O
40,in,O
40,patients,O
40,with,O
40,SARS,O
40,‐,O
40,CoV,O
40,‐,O
40,2,NUMBER
40,infection,CAUSE_OF_DEATH
40,treated,O
40,with,O
40,hydroxychloroquine,O
40,/,O
40,azithromycin,O
40,.,O
40,Therapeutic,O
40,Advances,O
40,in,O
40,Psychopharmacology,O
40,10,NUMBER
40,18,NUMBER
40,.,O
40,BMJ,O
40,.,O
40,Rapid,O
40,response,O
40,:,O
40,use,O
40,of,O
40,hydroxy,O
40,‐,O
40,chloroquine,O
40,19,NUMBER
40,.,O
40,Schrezenmeier,O
40,E,O
40,and,O
40,Dorner,PERSON
40,T.,O
40,Mechanisms,O
40,of,O
40,ac,O
40,‐,O
40,tion,O
40,of,O
40,hydroxychloroquine,O
40,and,O
40,chloroquine,O
40,:,O
40,implications,O
40,for,O
40,rheumatology,O
40,.,O
40,Nat,PERSON
40,Rev,PERSON
40,20,NUMBER
40,.,O
40,Zhou,PERSON
40,D,PERSON
40,.,O
40,Dai,PERSON
40,SM,O
40,and,O
40,Tong,O
40,Q.,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,:,O
40,a,O
40,recommendation,O
40,to,O
40,examine,O
40,the,O
40,effect,O
40,of,O
40,hydroxychloroquine,O
40,in,O
40,preventing,O
40,infection,CAUSE_OF_DEATH
40,and,O
40,21,NUMBER
40,.,O
40,U.S.,ORGANIZATION
40,Food,ORGANIZATION
40,&,ORGANIZATION
40,Drug,ORGANIZATION
40,Administration,ORGANIZATION
40,.,O
40,Hydrochloroquine,O
40,or,O
40,chloroquine,O
40,for,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,:,O
40,drug,O
40,safety,O
40,commu,O
40,‐,O
40,nication,O
40,FDA,ORGANIZATION
40,cautions,O
40,against,O
40,use,O
40,outside,O
40,of,O
40,the,O
40,hospital,O
40,setting,O
40,or,O
40,a,O
40,clinical,O
40,trial,O
40,due,O
40,to,O
40,hydroxychloroquine,O
40,‐,O
40,or,O
40,‐,O
40,chloroquine,O
40,‐,O
40,covid,O
40,‐,O
40,19drug,NUMBER
40,‐,O
40,safety,O
40,‐,O
40,communication,O
40,‐,O
40,fda,O
40,‐,O
40,cautions,O
40,‐,O
40,againstuse,O
40,(,O
40,ac,O
40,‐,O
40,cessed,O
40,02,DATE
40,May,DATE
40,2020,DATE
40,),O
40,.,O
40,22,NUMBER
40,.,O
40,Liu,PERSON
40,X,PERSON
40,.,O
40,Li,PERSON
40,Z,PERSON
40,.,O
40,Liu,PERSON
40,Z,PERSON
40,.,O
40,et,O
40,al,O
40,.,O
40,Potential,O
40,therapeutic,O
40,effects,O
40,of,O
40,dipyridamole,O
40,in,O
40,the,O
40,severely,O
40,ill,O
40,patients,O
40,product,O
40,/,O
40,3557,DATE
40,/,O
40,smpc,O
40,(,O
40,accessed,O
40,05,DATE
40,May,DATE
40,2020,DATE
40,),O
40,.,O
40,dipyridamole.html,O
40,(,O
40,ac,O
40,‐,O
40,cessed,O
40,05,DATE
40,May,DATE
40,2020,DATE
40,),O
40,.,O
40,31,NUMBER
40,.,O
40,Cai,O
40,Q,O
40,.,O
40,Yang,PERSON
40,M,O
40,.,O
40,Liu,PERSON
40,D,O
40,.,O
40,et,O
40,al,O
40,.,O
40,Experimen,O
40,‐,O
40,tal,O
40,treatment,O
40,with,O
40,favipiravir,O
40,for,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,:,O
40,an,O
40,open,O
40,‐,O
40,label,O
40,con,O
40,‐,O
40,trol,O
40,study,O
40,.,O
40,Engineering,O
40,(,O
40,Beijing,CITY
40,),O
40,.,O
40,32,NUMBER
40,.,O
40,Young,O
40,BE,O
40,.,O
40,Ong,PERSON
40,SWX,PERSON
40,.,O
40,Kalimuddin,PERSON
40,S,PERSON
40,.,O
40,et,O
40,al,O
40,.,O
40,Epidemiologic,O
40,features,O
40,and,O
40,clinical,O
40,course,O
40,of,O
40,patients,O
40,infected,O
40,with,O
40,SARS,O
40,‐,O
40,CoV,O
40,‐,O
40,2,NUMBER
40,in,O
40,Singapore,COUNTRY
40,.,O
40,33,NUMBER
40,.,O
40,Cao,PERSON
40,B,PERSON
40,.,O
40,Wang,O
40,Y,O
40,.,O
40,Wen,PERSON
40,D,PERSON
40,.,O
40,et,O
40,al,O
40,.,O
40,A,O
40,trial,O
40,of,O
40,lopinavirritonavir,O
40,in,O
40,adults,O
40,hospitalized,O
40,with,O
40,34,NUMBER
40,.,O
40,Medicines.org.uk,URL
40,.,O
40,Norvir,MISC
40,100,NUMBER
40,mg,O
40,film,O
40,‐,O
40,coated,O
40,product,O
40,/,O
40,510,NUMBER
40,/,O
40,smpc,O
40,(,O
40,accessed,O
40,03,DATE
40,March,DATE
40,2020,DATE
40,),O
40,.,O
40,35,NUMBER
40,.,O
40,Rossignol,ORGANIZATION
40,JF,ORGANIZATION
40,.,O
40,Ni,MISC
40,‐,O
40,tazoxanide,O
40,:,O
40,a,O
40,first,ORDINAL
40,‐,O
40,in,O
40,‐,O
40,class,O
40,broadspectrum,O
40,antiviral,O
40,agent,O
40,.,O
40,An,O
40,‐,O
40,tivir,O
40,Res,O
40,2014,DATE
40,;,O
40,110,NUMBER
40,:,O
40,36,NUMBER
40,.,O
40,Padmanabhan,PERSON
40,S.,PERSON
40,Potential,PERSON
40,dual,O
40,therapeu,O
40,‐,O
40,tic,O
40,approach,O
40,against,O
40,SARS,O
40,‐,O
40,CoV,O
40,‐,O
40,2,NUMBER
40,/,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,with,O
40,Nitazoxanide,O
40,and,O
40,Hydroxychloroquine,O
40,.,O
40,2020,DATE
40,.,O
40,37,NUMBER
40,.,O
40,Yao,PERSON
40,X,PERSON
40,.,O
40,Ye,PERSON
40,F,PERSON
40,.,O
40,Zhang,O
40,M,O
40,.,O
40,et,O
40,al,O
40,.,O
40,In,O
40,vitro,O
40,antiviral,O
40,activity,O
40,and,O
40,projection,O
40,of,O
40,optimized,O
40,dosing,O
40,de,O
40,‐,O
40,sign,O
40,of,O
40,hydroxychloroquine,O
40,for,O
40,the,O
40,treatment,O
40,of,O
40,severe,O
40,acute,O
40,res,O
40,‐,O
40,piratory,O
40,syndrome,O
40,coronavirus,O
40,2,NUMBER
40,(,O
40,SARS,O
40,‐,O
40,CoV,O
40,‐,O
40,2,NUMBER
40,),O
40,.,O
40,Clin,O
40,Infect,O
40,Dis,O
40,.,O
40,38,NUMBER
40,.,O
40,Wang,PERSON
40,M,O
40,.,O
40,Cao,PERSON
40,R,PERSON
40,.,O
40,Zhang,PERSON
40,L,PERSON
40,.,O
40,et,O
40,al,O
40,.,O
40,Remdesivir,O
40,and,O
40,chloroquine,O
40,ef,O
40,‐,O
40,fectively,O
40,inhibit,O
40,the,O
40,recently,DATE
40,emerged,O
40,novel,O
40,coronavirus,O
40,(,O
40,2019,DATE
40,‐,O
40,nCoV,O
40,),O
40,in,O
40,vitro,O
40,.,O
40,Cell,O
40,Res,O
40,2020,DATE
40,;,O
40,30,NUMBER
40,:,O
40,269271,NUMBER
40,.,O
40,PROPS,O
40,(,O
40,ac,O
40,‐,O
40,cessed,O
40,05,DATE
40,May,DATE
40,2020,DATE
40,),O
40,.,O
40,city,O
40,=,O
40,&,O
40,dist,O
40,=,O
40,&,O
40,Search,O
40,=,O
40,Search,O
40,(,O
40,accessed,O
40,27,NUMBER
40,March,DATE
40,27,DATE
40,.,O
40,Borrell,PERSON
40,B.,PERSON
40,New,PERSON
40,York,PERSON
40,clinical,O
40,trial,O
40,quietly,O
40,tests,O
40,heart,O
40,‐,O
40,burn,O
40,remedy,O
40,against,O
40,coronavirus,O
40,.,O
40,Science,O
40,.,O
40,29,NUMBER
40,.,O
40,Taylor,PERSON
40,D,O
40,.,O
40,Barnes,PERSON
40,TRE,O
40,and,O
40,Young,O
40,AH,O
40,.,O
40,The,O
40,Maudsley,O
40,prescribing,O
40,guidelines,O
40,in,O
40,psychia,O
40,‐,O
40,try,O
40,.,O
40,13th,ORDINAL
40,ed,O
40,.,O
40,Hoboken,CITY
40,.,O
40,NJ,STATE_OR_PROVINCE
40,:,O
40,Wiley,PERSON
40,.,O
40,2018,DATE
40,.,O
40,40,NUMBER
40,.,O
40,BMJ,O
40,Best,O
40,Practice,O
40,.,O
40,Coronavirus,O
40,disease,CAUSE_OF_DEATH
40,2019,DATE
40,41,DATE
40,.,O
40,Grein,PERSON
40,J,PERSON
40,.,O
40,Norio,PERSON
40,Ohmagari,PERSON
40,N,PERSON
40,.,O
40,Shin,PERSON
40,D,PERSON
40,.,O
40,et,O
40,al,O
40,.,O
40,Compassionate,O
40,use,O
40,of,O
40,remdesivir,O
40,for,O
40,patients,O
40,D,O
40,Bishara,PERSON
40,.,O
40,C,O
40,Kalafatis,PERSON
40,et,O
40,al,O
40,.,O
40,alphain,O
40,in,O
40,patients,O
40,with,O
40,mild,O
40,to,O
40,moderate,O
40,novel,O
40,coronavirus,O
40,pneumonia,CAUSE_OF_DEATH
40,.,O
40,Chin,PERSON
40,Med,PERSON
40,J,PERSON
40,(,O
40,Engl,ORGANIZATION
40,),O
40,2020,DATE
40,;,O
40,42,NUMBER
40,.,O
40,Gilead,ORGANIZATION
40,sci,O
40,‐,O
40,ences,O
40,initiates,O
40,two,NUMBER
40,phase,O
40,3,NUMBER
40,studies,O
40,of,O
40,investigational,O
40,antiviral,O
40,remdesivir,O
40,for,O
40,the,O
40,gilead,O
40,‐,O
40,sciences,O
40,‐,O
40,initiates,O
40,‐,O
40,two,NUMBER
40,‐,O
40,phase,O
40,‐,O
40,3,NUMBER
40,‐,O
40,stud,O
40,‐,O
40,iesof,O
40,‐,O
40,investigational,O
40,‐,O
40,antiviral,O
40,‐,O
40,remdesivir,O
40,‐,O
40,for,O
40,‐,O
40,thetreatment,O
40,‐,O
40,of,O
40,‐,O
40,covid,O
40,‐,O
40,19,NUMBER
40,(,O
40,accessed,O
40,27,DATE
40,March,DATE
40,2020,DATE
40,),O
40,.,O
40,46,NUMBER
40,.,O
40,Medicines.org.uk,URL
40,.,O
40,Rib,O
40,‐,O
40,avirin,O
40,200,NUMBER
40,mg,O
40,film,O
40,‐,O
40,coated,O
40,product,O
40,/,O
40,7108,DATE
40,/,O
40,smpc,O
40,.,O
40,(,O
40,accessed,O
40,28,DATE
40,March,DATE
40,2020,DATE
40,),O
40,.,O
40,news,O
40,‐,O
40,releases,O
40,/,O
40,nih,O
40,‐,O
40,clinical,O
40,‐,O
40,trial,O
40,‐,O
40,remdesivir,O
40,‐,O
40,treat,O
40,‐,O
40,covid,O
40,‐,O
40,19,NUMBER
40,‐,O
40,begins,O
40,(,O
40,accessed,O
40,27,DATE
40,March,DATE
40,2020,DATE
40,),O
40,.,O
40,44,NUMBER
40,.,O
40,MedicineNet,O
40,.,O
40,Remdesivir,O
40,(,O
40,RDV,O
40,),O
40,:,O
40,experimental,O
40,remdesivir_rdv,O
40,(,O
40,accessed,O
40,27,DATE
40,March,DATE
40,2020,DATE
40,),O
40,.,O
40,48,NUMBER
40,.,O
40,Ritchie,PERSON
40,AI,O
40,and,O
40,Singanayagam,PERSON
40,A.,PERSON
40,Immuno,PERSON
40,suppression,O
40,for,O
40,hyperinflammation,O
40,in,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,:,O
40,a,O
40,double,O
40,‐,O
40,edged,O
40,sword,O
40,?,O
40,Lancet,O
40,2020,DATE
40,;,O
40,395,NUMBER
40,:,O
40,1111,DATE
40,.,O
40,45,NUMBER
40,.,O
40,Zeng,PERSON
40,YM,PERSON
40,.,O
40,Xu,O
40,XL,O
40,.,O
40,He,O
40,XQ,O
40,.,O
40,et,O
40,al,O
40,.,O
40,Comparative,O
40,effec,O
40,‐,O
40,tiveness,O
40,and,O
40,safety,O
40,of,O
40,ribavirin,O
40,plus,O
40,interferonalpha,O
40,.,O
40,lopinavir,O
40,/,O
40,ritonavir,O
40,plus,O
40,interferon,O
40,‐,O
40,alpha,O
40,and,O
40,ribavirin,O
40,plus,O
40,lopinavir,O
40,/,O
40,ritonavir,O
40,plus,O
40,interferon,O
40,‐,O
40,healthcare,O
40,workers,O
40,against,O
40,COVID,O
40,‐,O
40,19,NUMBER
40,(,O
40,BRACE,O
40,),O
40,.,O
40,50,NUMBER
40,.,O
40,Mahase,PERSON
40,E.,PERSON
40,Covid,PERSON
40,‐,O
40,19,NUMBER
40,:,O
40,what,O
40,treatments,O
40,are,O
40,be,O
40,‐,O
40,ing,O
40,investigated,O
40,?,O
40,BMJ,O
40,2020,DATE
40,;,O
40,368,NUMBER
40,:,O
40,m1252,O
40,.,O
